Back

 

NAME OF THE HOSPITALE S NURSING COLLEGE HOSPITAL, VILLUPURAM TN.
ADDRESSNO:13,HOSPITAL ROAD,VANDIMEDU, VILLUPURAM
CONTACT NUMBER9443147949
AVAILABLE SPECIALITIESDIALYSIS
GENERAL MEDICINE
GENERAL SURGERY
GENITOURINARY SURGERY
GYNAECOLOGY OBSTETRIC SURGERY
MEDICAL ONCOLOGY
NEUROLOGY
ORTHOPEDIC TRAUMA
SURGICAL GASTRO ENTEROLOGY
SURGICAL ONCOLOGY
VASCULAR SURGERIES

Packages Rate
CM0076 : INGUINAL BLOCK DISSECTION ONE SIDE 13275
CM0077 : ABDOMNO PERINEAL RESECTION (APR) + SACRECTOMY 41040
CM0078-A : LAPROSCOPIC APR 46440
CM0078-B : EXTRALEVATOR APR 34740
CM0078-C : TRANS ABDOMINAL 34740
CM0078-D : TRANS ANAL 34740
CM0078-E : INTERSPHINCTERIC RESECTION 34740
CM0078-F : LOW ANTERIOR RESECTION 39240
CM0079 : ABDOMINAL WALL TUMORS RESECTION WITH RECONSTRUCTION 40050
CM0080 : ABDOMINAL WALL TUMORS RESECTION WITHOUT RECONSTRUCTION 28800
CM0081 : BILATERAL PELVIC LYMPH NODE DISSECTION(BPLND) ANY SITE 19800
CM0082-A : RADICAL VAGINECTOMY WITHOUT RECONSTRUCION a) WITH LND 25425
CM0082-B : RADICAL VAGINECTOMY WITHOUT RECONSTRUCION b) WITHout LND 23175
CM0083-A : RADICAL VAGINECTOMY WITH RECONSTRUCION a) WITH LND 37125
CM0083-B : RADICAL VAGINECTOMY WITH RECONSTRUCION b) WITHOUT LND 32625
CM0084-A : RADICAL HYSTERECOMY+BILATERAL PELVIC LYMPH NODE DISSECTION+BILATERAL SALPHINGO OOPHERECTOMY 33525
CM0084-B : OVARIAN TRANSPOSITION 39825
CM0085-A : ANTERIOR EXENTRATION - ANY SITE 51975
CM0085-B : POSTERIOR EXENTRATION- ANY SITE 37575
CM0086 : TOTAL PELVIC EXENTRATION - ANY SITE 63675
CM0087 : EXTRALEVATOR EXENTRATION - ANY SITE 36225
CM0088 : SUPRALEVATOR EXENTRATION - ANY SITE 36225
CM0089 : TOTAL ABDOMINAL HYSTERECTOMY+BILATERAL SALPHINGO OOPHERECTOMY+BILATERAL PELVIC LYMPH NODE DISSECTION+OMENTECTOMY 31230
CM0090-A : RETRO PERITONEAL LYMPH NODE DISSECTION(RPLND) (FOR RESIDUAL DISEASES /STAGING 19125
CM0090-B : RETRO PERITONEAL LYMPH NODE DISSECTION(RPLND) (FOR RESIDUAL DISEASES /WITH VASCULAR RECONSTRUCTION 28350
CM0091-A : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY 54225
CM0091-B : OESOPHAGECTOMY WITH THREE FIELD LYMPADENECTOMY 65475
CM0092-A : VERMILIONECTOMY WITHOUT WEDGE EXCISION 15075
CM0092-B : VERMILIONECTOMY WITH WEDGE EXCISION 16875
CM0093 : EMASCULATION 22230
CM0094 : PALATECTOMY ANY TYPE 22725
CM0095 : RADICAL TRACHELECTOMY 30825
CM0096 : SUBSTERNAL BYPASS 24525
CM0097 : ABBE OPERATION 16875
CM0098 : CYTOREDUCTIVE SURGERY 20925
CM0099 : VULVECTOMY 13725
CM0100-a-I : BREAST CANCER - Dose Dense AC (Adriamycin/Cyclophosphamide) ; (Day 1: Doxorubicin 60mg/m2 IV, Cyclophosphamide 600mg/m2 IV) ; Repeat cycle - every 14 days for 4 cycles; Followed by Paclitaxel for 4 cycles 3000
CM0100-a-II : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 14 days for 4 cycles 7000
CM0100-b : BREAST CANCER - TC (Doectaxel & Cyclophosphamide) ; Day 1: Docetaxel 75mg/m2 IV, Cyclophosphamide 600mg/m2 IV ; Repeat cycle - every 21 days for 4 cycles 6000
CM0100-c : BREAST CANCER - CMF (Cyclophosphamide/Methotrexate/Fluorouracil) - (includes day 1 & day 8) ; Days 1-14: Cyclophosphamide 100mg/m2 orally ; Days 1 and 8: Methotrexate 40mg/m2 IV ; Days 1 and 8: 5-fluorouracil 600mg/m2 IV. ; Repeat cycle - every 28 days for 6 cycles 2700
CM0100-d : BREAST CANCER - EC (Epirubicin/Cyclophosphamide) ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 830mg/m2 IV. ; Repeat cycle - every 21 days for 8 cycles 5100
CM0100-e-I : BREAST CANCER - FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) - followed by Docetaxel or followed by weekly Paclitaxel) ; Day 1: 5-fluorouracil 500mg/m2 IV ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle every 21 days for 3 cycles 5100
CM0100-e-II : BREAST CANCER - Docetaxel - (Preceeded by FEC/CEF ) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle - every 21 days for 3 cycles 5500
CM0100-e-III : BREAST CANCER - Paclitaxel - weekly - (Preceeded by FEC/CEF ) ; Paclitaxel 100mg/m2 IV ; Repeat cycle - once weekly for 8 weeks 3500
CM0100-f-I : BREAST CANCER - FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) - followed by weekly Paclitaxel ; 5-fluorouracil 500mg/m2 IV Days 1 and 8 OR 1 and 4: ; Day 1: Doxorubicin 50mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle - every 21 days for 6 cycles 3200
CM0100-f-II : BREAST CANCER - Paclitaxel - weekly - Preceeded by FAC ; Paclitaxel 80mg/m2 IV ; Repeat Cycle weekly for 12 weeks. 3500
CM0100-g : BREAST CANCER - TAC (Docetaxel/Adriamycin/Cyclophosphamide) ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 5600
CM0100-h-I : BREAST CANCER - AC - followed by Paclitaxel + Trastuzumab +/- Pertuzumab ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle - every 21 days for 4 cycle 3000
CM0100-h-II : BREAST CANCER - Paclitaxel (Preceeded by AC) ; (To be choosen along with Trastuzumab package - CM0100-h-III or CM0100-h-IV or CM0100-h-V) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. 3500
CM0100-h-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with Paclitaxel Cycle 1, 4, 7, 10 and standalone for the upto 1 year every 21 days) 30500
CM0100-h-IV : BREAST CANCER - Trastuzumab 4mg (Followed by Trastuzumab 2mg subsequent weeks) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-h-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 2mg/kg IV weekly Till one year from Day 1 of AC. ; (to be approved with Paclitaxel Cycles 2 - 12 and standalone for the upto 1 year every week) 11500
CM0100-i-I : BREAST CANCER - TC (Docetaxel/Carboplatin) ; (To be choosen along with Trastuzumab package - CM0100-i-II or CM0100-i-III or CM0100-i-IV) ; Day 1: Docetaxel 75mg/m2 IV; Carboplatin AUC 6mg per min/mL IV. ; every 21 days for 6 cycles 7100
CM0100-i-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with TC package CM0100-i-I) ; Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with TC Cycle 1 to 6 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 18 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-i-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with TC package CM0100-i-I) ; Day 1: Trastuzumab 4mg/kg IV ; (First dose - only to be approved with TC Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-i-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses - Weekly) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 17 weeeks may overlap with TC Cycles 2 - 6. To be followed by Trastuzumab (6mg) package upto 1 year 11500
CM0100-j-I : BREAST CANCER - AC - followed by Docetaxel + Trastuzumab ; Day 1: Doxorubicin 60mg/m2 IV; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 3000
CM0100-j-II : BREAST CANCER - Docetaxel (preceeded by AC) + Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-j-III or CM0100-j-IV or CM0100-j-V) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles 5400
CM0100-j-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel package CM0100-j-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat every 21 days till 1 year ; (to be approved with Docetaxel Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) or from 13 th week after completion of 12 weeks of weekly Trastuzumab - upto 1 year every 21 days) 30500
CM0100-j-IV : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel package CM0100-j-II) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-j-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) 11500
CM0100-k-I : BREAST CANCER - Docetaxel + Cyclophosphamide - with Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-k-II or CM0100-k-III or CM0100-k-IV) ; Day 1: Docetaxel 75mg/m2 IV; Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 5000
CM0100-k-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Day 1: Trastuzumab 6mg/kg IV ; (to be approved with Docetaxel + Cyclophosphamide Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-k-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel + Cyclophosphamide Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-k-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel + Cyclophosphamide Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) 11500
CM0100-L-I : BREAST CANCER - Paclitaxel - (with Trastuzumab) ; (To be choosen along with Trastuzumab package - CM0100-L-III or CM0100-L-IV) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. 3000
CM0100-L-II : BREAST CANCER - Trastuzumab (6mg) ; trastuzumab 6mg/kg IV ; Repeat every 21 days ; (to be approved after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-L-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-L-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Day 1: Trastuzumab 2mg/kg IV weekly ; (to be approved with Paclitaxel Cycles 2 - 12. May be approved as standalone for the upto 1 year every week or Trastuzumab 6mg Package may be used once every 21 days upto 1 year) 11500
CM0100-M : BREAST CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0101-a-I : BLADDER CANCER - DDMVAC ; Day 1: Methotrexate 30mg/m2 IV; Day 2: Vinblastine 3mg/m2 IV, doxorubicin 30mg/m2 IV, cisplatin 70mg/m2 IV; ; Repeat every 2 weeks for 3-4 cycles 3800
CM0101-a-II : BLADDER CANCER - Gemcitabine + cisplatin ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV; Day 2: Cisplatin 70mg/m2. ; Repeat every 4 weeks for 4 cycles. 6400
CM0101-a-III : BLADDER CANCER - Cisplatin + methotrexate + vinblastine (CMV) ; Day 1: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV; Day 2: Cisplatin 100mg/m2 IV, leucovorin 15mg oral or IV every 6 hours for 4 doses; Day 8: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV Day 9: Leucovorin 15mg oral every 6 hours for 4 doses ; Repeat every 3 weeks for 3 cycles. 4800
CM0101-b : BLADDER CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-i-a : LUNG CANCER - Mesothelioma - Pemetrexed + cisplatin ; Day 1: Pemetrexed 500mg/m2 IV, cisplatin 75mg/m2 ; Repeat every 21 days up to 12 cycles. 14500
CM0102-i-b : LUNG CANCER - Mesothelioma - Pemetrexed + carboplatin ; Day 1: Pemetrexed 500mg/m2 IV, carboplatin AUC 5mg/min/mL IV. ; Repeat every 21 days for a max of 9 cycles. 16500
CM0102-i-c : LUNG CANCER - Mesothelioma - Cisplatin & Gemcitabine ; Day 1: Cisplatin 80-100mg/m2 IV ; Days 1, 8, and 15: Gemcitabine 1000-1250mg/m2 IV ; Repeat every 21 - 28 days for 6 cycles. 7600
CM0102-i-d : LUNG CANCER - Mesothelioma - Vinorelbine ; Vinorelbine 25-30mg/m2 (max 60mg) IV ; Repeat every week for 12 weeks. 9000
CM0102-i-e : LUNG CANCER - Mesothelioma - Pemetrexed ; Day 1: Pemetrexed 500mg/m2 IV. ; Repeat every 21 days for 4 cycles (If First line) or Repeat every 21 days for 8 cycles (If Second line) 14500
CM0102-i-f : LUNG CANCER - Mesothelioma - Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1250mg/m2 IV. ; Repeat every 28 days for a max of 10 cycles. 7600
CM0102-i-g : LUNG CANCER - Mesothelioma - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-ii-a : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (i) ; Days 1 and 8: Cisplatin 50mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 25mg/m2 IV ; (or) ; Day 1: Cisplatin 100mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 30mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. 33600
CM0102-ii-b : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (ii) ; Day 1: Cisplatin 75-80mg/m2 ; Days 1 and 8: Vinorelbine 25-30mg/m2. ; Repeat every 3 weeks for 4 cycles 17900
CM0102-ii-c : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 100mg/m2 IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles 4900
CM0102-ii-d : LUNG CANCER - NSCLC - Cisplatin & Docetaxel ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. 6300
CM0102-ii-e : LUNG CANCER - NSCLC - Cisplatin & Gemcitabine ; Day 1: Cisplatin 75mg/m2 IV ; Days 1 and 8: Gemcitabine 1,250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles 6100
CM0102-ii-f : LUNG CANCER - NSCLC - Pemetrexed + cisplatin (for Non Squamous Cell CA) ; Day 1: Cisplatin 75mg/m2 IV, pemetrexed 500mg/m2 IV. ; Repeat every - 21 days for 4 cycles. 14500
CM0102-ii-g : LUNG CANCER - NSCLC - Paclitaxel/Carboplatin ; Day 1: Paclitaxel 200mg/m2 IV, carboplatin AUC 6mg per min/mL IV. ; Repeat cycle every 3 weeks for 4 cycles. 8100
CM0102-ii-h : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Days 1, 8, 29 and 36: Cisplatin 50mg/m2 IV ; Days 1-5 and 29-33: Etoposide 50mg/m2 IV ; Concurrent thoracic radiotherapy 1.8Gy/day for 5 days/week (total dose, 61Gy). 8500
CM0102-ii-i : LUNG CANCER - NSCLC - Cisplatin & Vinblastine ; Days 1 and 29: Cisplatin 100mg/m2 IV ; Days 1, 8, 15, 22 and 29: Vinblastine 5mg/m2 IV ; concurrent thoracic radiotherapy (total dose, 60Gy). 8200
CM0102-ii-j : LUNG CANCER - NSCLC - Carboplatin + Pemetrexed ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 4 cycles. 16500
CM0102-ii-k : LUNG CANCER - NSCLC - Cisplatin + Pemetrexed ; Day 1: Cisplatin 75 mg/m2 IV. ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 3 cycles. 14900
CM0102-ii-l : LUNG CANCER - NSCLC - Paclitaxel + Carboplatin ; Paclitaxel 45mg/m2 IV + carboplatin AUC 2mg per min/mL IV ; with concurrent thoracic radiotherapy (total dose, 60Gy) ; Repeat weekly for 6 weeks 3300
CM0102-ii-m : LUNG CANCER - NSCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-iii-a : LUNG CANCER - SCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 60mg/m2 IV, Days 1-3: Etoposide 120mg/m2 IV. ; Repeat cycle every 3 weeks for at least 4 cycles. ;(OR) ; Day 1: Cisplatin 80mg/m2 IV, Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4-6 cycles. 4900
CM0102-iii-b : LUNG CANCER - SCLC - Carboplatin & Etoposide ; Day 1: Carboplatin AUC 5-6mg per min/mL IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 21 days or 28 days for 4 - 6 cycles 6500
CM0102-iii-c : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. 5800
CM0102-iii-d : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1 and 8: Cisplatin 30mg/m2 IV, irinotecan 65mg/m2 IV. ; Repeat cycle every 3 weeks for 4-6 cycles. 5700
CM0102-iii-e : LUNG CANCER - SCLC - Carboplatin & Irinotecan ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 50mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles 7700
CM0102-iii-f : LUNG CANCER - SCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-i-a : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 2mg/min/mL IV. ; Repeat weekly for 5 weeks 3300
CM0103-i-b : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV. 12000
CM0103-i-c : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5 and Days 22-26: 5-FU 800 mg/m2 IV ; Repeat every 21 days for 2 cycles 7100
CM0103-i-d : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil + Oxaliplatin + Leucovorin ; Day 1: Oxaliplatin 85mg/m2, leucovorin 200mg/m2 and 5-FU 400mg/m2 bolus, with 1,600mg/m2 infusion; ; Repeat every 14 days for 6 cycles 4600
CM0103-i-e : ESOPHAGEAL CANCER - Neo Adjuvant - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks 2500
CM0103-i-f : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV 25800
CM0103-i-g : ESOPHAGEAL CANCER - Neo Adjuvant - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks. 8900
CM0103-i-h : ESOPHAGEAL CANCER - Neo Adjuvant - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV, cisplatin 30mg/m2 IV. 9700
CM0103-i-i : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV infusion. ; Repeat cycle weekly for 5 weeks. 5500
CM0103-i-j : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 12200
CM0103-i-k : ESOPHAGEAL CANCER - Neo Adjuvant - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-ii-a : ESOPHAGEAL CANCER - Peri-Operative - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV continuous infusion once daily; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 16700
CM0103-ii-b : ESOPHAGEAL CANCER - Peri-Operative - EOF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 18700
CM0103-ii-c : ESOPHAGEAL CANCER - Peri-Operative - EOC (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 7800
CM0103-ii-d : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV ; Repeat cycle every 28 days for 2-4 cycles 12000
CM0103-ii-e : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cyclesCycled every 21 days for 2 cycles 7100
CM0103-ii-f : ESOPHAGEAL CANCER - Peri-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-iii-a : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (i) ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV, followed by 4 weeks break and CCRT ; RT Days 1-4 and 23-25: 5-FU 400mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV. 25400
CM0103-iii-b : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 200mg/m2 IV, 5-FU 400mg/m2 IV push and 5-FU 600mg/m2 infusion 9000
CM0103-iii-c : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily; ; Repeat every 28 days; 1 cycle before and 2 cycles after chemoradiation 3100
CM0103-iii-d : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily, ; once weekly for 5 weeks. 1600
CM0103-iii-e : ESOPHAGEAL CANCER - Post-Operative - FluorouracilDays 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV continuous infusion over 24 hours daily, ; once weekly for 5 weeks.once weekly for 5 weeks. 6500
CM0103-iii-f : ESOPHAGEAL CANCER - Post-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-iv-a : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV 12000
CM0103-iv-b : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cycles 7100
CM0103-iv-c : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day continuous IV infusion. 25800
CM0103-iv-d : ESOPHAGEAL CANCER - Definitive - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks 2000
CM0103-iv-e : ESOPHAGEAL CANCER - Definitive - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks 8900
CM0103-iv-f : ESOPHAGEAL CANCER - Definitive - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV and carboplatin 2mg/min/mL IV ; Repeat weekly for 5 weeks. 3300
CM0103-iv-g : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (i) ; Days 1 and 22: Docetaxel 60mg/m2 IV ; Days 1 and 22: Cisplatin 60-80mg/m2 IV given for 1 cycle 8900
CM0103-iv-h : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (ii) ; Day 1: Docetaxel 20-30mg/m2 IV ; Day 1: Cisplatin 20-30mg/m2 IV ; Repeat weekly for 5 weeks 3000
CM0103-iv-i : ESOPHAGEAL CANCER - Definitive - Cisplatin with Paclitaxel ; Days 1, 8, 15, and 22: Paclitaxel 60mg/m2 IV ; Day 1: Cisplatin 75mg/m2 IV given for 1 cycle. 13100
CM0103-iv-j : ESOPHAGEAL CANCER - Definitive - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV ; Days 1, 8, 22, and 29: Cisplatin 30mg/m2 IV. 9700
CM0103-iv-k : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV ; Repeat cycle weekly for 5 weeks. 5500
CM0103-iv-l : ESOPHAGEAL CANCER - Definitive - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 PO twice daily. ; Repeat cycle weekly for 5 weeks. 12200
CM0103-iv-m : ESOPHAGEAL CANCER - Definitive - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-i-a : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV, carboplatin AUC 2mg/min/mL IV. ; Repeat cycle weekly for 5 weeks. 3300
CM0104-i-b : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1000mg/m2/day IV 12000
CM0104-i-c : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV once daily, 5-FU 800mg/m2/day IV ; Repeat cycle every 21 days for 2 cycles. 7100
CM0104-i-d : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (i)Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV. 25800
CM0104-i-e : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (ii)Day 1: Oxaliplatin 85mg/m2 and leucovorin 400mg/m2 followed by 5-FU 400mg/m2 bolus, then 800mg/m2 24-hour continuous infusion over days 1 and 2; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT; 6 bimonthly (14 days) cycles. 6100
CM0104-i-f : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 2000
CM0104-i-g : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks 8900
CM0104-i-h : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45-50mg/m2 IV weekly ; Days 1-5: 5-FU 300mg/m2 IV ; Repeat cycle weekly for 5 weeks 5500
CM0104-i-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 3100
CM0104-i-j : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-ii-a : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV, cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2/day IV ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 16700
CM0104-ii-b : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - EOF (Epirubicin/ oxaliplatin /Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 18700
CM0104-ii-c : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - epirubicin + cisplatin + capecitabine ; Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 5900
CM0104-ii-d : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF modification (epirubicin + oxaliplatin + capecitabine) ; Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperativelyRepeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 7800
CM0104-ii-e : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Fluorouracil & Cisplatin ; Day 1: Cisplatin 75-80mg/m2 IV ; Days 1-5: 5-FU 800mg/m2 IV ; Repeat cycle every 28 days for 2-3 cycles preoperatively and 3-4 cycles postoperatively for a total of 6 cycles. 6900
CM0104-ii-f : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-iii-a : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (i) ; Cycles 1, 3, and 4 (before and after radiation) Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2/day IV ; Repeat cycle every 28 days. ; Cycle 2 (with radiation) Days 1-4 and 31-33: Leucovorin 20mg/m2 IVP ; Days 1-4: 5-FU 400mg/m2/day IVP. ; Repeat cycle every 35 days 25400
CM0104-iii-b : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV, 5-FU 400mg/m2 IV and 5-FU 1200mg/m2 infusion; ; 1 cycle before and 2 cycles after chemoradiation. ; Repeat cycle every 28 daysRepeat cycle every 28 days 14900
CM0104-iii-c : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily. ; Repeat cycle every 28 days; 1 cycle before and 2 cycles after chemoradiation. 3100
CM0104-iii-d : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily; weekly for 5 weeks. 1600
CM0104-iii-e : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil ; Days 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV; ; weekly for 5 weeks. 6500
CM0104-iii-f : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Cisplatin + capecitabine ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 6 cycles. 4000
CM0104-iii-h : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Oxaliplatin + capecitabine ; Day 1: Oxaliplatin 130mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 8 cycles.Repeat cycle every 21 days for 8 cycles. 6000
CM0104-iii-i : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0105-i-a : COLORECTAL CARCINOMA - FOLFOX (Stage - III) - (Oxaliplatin, Leucovorin, 5-FU) ; Day 1: Oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV , 5-FU 400mg/m2 IV, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) over 46-48-hour continuous infusion. ; Repeat cycle every 2 weeks- upto 12 cycles 8000
CM0105-i-b : COLORECTAL CARCINOMA - CAPEOX (Stage - III) (Oxaliplatin, Capecitabine) ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Days 1-14: Capecitabine 1,000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 6 months 6500
CM0105-i-c : COLORECTAL CARCINOMA - FLOX (Stage - III) (5-FU, leucovorin, oxaliplatin) ; 5-FU 500mg/m2 IV bolus weekly x 6, leucovorin 500mg/m2 IV weekly x 6, each ; oxaliplatin 85mg/m2 IV on weeks 1, 3, and 5 ; 8-week cycle x 3 cycles ; 30000
CM0105-i-d : COLORECTAL CARCINOMA - Capecitabine ; Capecitabine 1,250mg/m2 - BD / TDS D 1-14 ; every 3 weeks * 24 weeks 4300
CM0105-i-e : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (i) ; Leucovorin 500mg/m2 weekly x 6 weeks, ; 5-FU 500mg/m2 weekly x 6 weeks. ; Repeat cycle every 8 weeks for 4 cycles. 23700
CM0105-i-f : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (ii)Simplified biweekly infusion. ; Leucovorin 400mg/m2 IV, 5-FU bolus 400mg/m2 and then 1,200mg/m2/day x 2 days (total 2,400mg/m2 over 46-48 hours) ; Repeat cycle every 2 weeks for 6 cycles. 5200
CM0105-i-g : COLORECTAL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0105-ii-a : COLORECTAL CARCINOMA - Concurrent - 5FU - with XRT ; Days 1-5 OR 1-7: 5-FU 225mg/m2 IV ; with External beam radiotherapy 3800
CM0105-ii-b : COLORECTAL CARCINOMA - Concurrent - Fluorouracil + Leucovorin - with XRT ; Days 1-4: 5-FU 400mg/m2 IV + leucovorin 20mg/m2 IV. ; Repeat cycle during weeks 1 and 5 of XRT. 6100
CM0105-ii-c : COLORECTAL CARCINOMA - Concurrent - Capecitabine - with XRT ; Capecitabine Tablet 825mg / m2 twice daily on Days 1-5 ; Repeat cycle weekly for 5 weeks. 1300
CM0105-ii-d : COLORECTAL CARCINOMA - Concurrent - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0106-i-a : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Cisplatin + doxorubicin ; Days 1-3: Doxorubicin 25mg/m2/day IV, ; Day 1: Cisplatin 100mg/m2 IV ; Repeat cycle every 3 weeks for 6 cycles 5600
CM0106-i-b-1 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - PRE OPERATIVE ; Days 1 and 28: Methotrexate 8g/m2 IV ; Days 7-9 and 34-36: Cisplatin 120mg/m2 by infusion for 72 hours. ; Days 9 and 36: Doxorubicin 60mg/m2 IV 24200
CM0106-i-b-2 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS < 90% ; Days 1, 48, 96, and 144: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 69, and 117: Methotrexate 8g/m2 IV ; Days 27, 75, and 123: Cisplatin 120mg/m2 by infusion for 72 hours. 40100
CM0106-i-b-3 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS > 90%Postoperative Chemotherapy (Necrosis 59100
CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also) 111505
CM0106-i-d : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Ifosfamide + cisplatin + epirubicin ; Day 1: Epirubicin 90mg/m2 IV, cisplatin 100mg/m2 IV ; Days 2-4: Ifosfamide 2.0g/m2 with mesna ; Repeat cycle every 21 days. (3 cycles preoperatively and 3 cycles postoperatively). 8300
CM0106-ii-a : Other bone tumors - Chordroma - Imatinib ; Imatinib 800 mg once daily 4500
CM0106-ii-b : Other bone tumors - Chordroma - Imatinib + cisplatin ; Imatinib 400mg OD + cisplatin 25mg/m2 weekly. 4500
CM0106-ii-c : Other bone tumors - Chordroma - Imatinib + sirolimus ; Imatinib 400mg OD + sirolimus 2mg OD 6000
CM0106-ii-d : Other bone tumors - Chordroma - Erlotinib ; Erlotinib 150mg OD 2200
CM0106-ii-e : Other bone tumors - Chordroma - Sunitinib ; Sunitinib 37.5mg OD 28500
CM0106-iii-a :Other bone tumors - Giant Cell Tumor of Bone - Denosumab ; Denosumab 120mg subcutaneous on Week 1,2 and 3 of a 4 week cycle 56000
CM0106-iii-b :Other bone tumors - Giant Cell Tumor of Bone - Interferon alfa ; interferon alfa- 2a thrice weekly 4600
CM0106-iii-c :Other bone tumors - Giant Cell Tumor of Bone - Peginterferon ; Peginterferon alfa-2a 1.0mcg/kg SQ injection weekly. 3500
CM0106-iv-a : VAC and IE cycles 6420
CM0106-iv-b : Other bone tumors - Mesenchymal Chordosarcoma VAIA ; Day 1: Vincristine 1.5mg/m2 IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 3 weeks. 7600
CM0106-v : Other bone tumors - Mesenchymal Chordosarcoma Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0107-a : WILMS TUMOR - Vincristine & Actinomycin D ; Dactinomycin 45mcg/kg - week - 0, 3, 6,9,12,15,18 ; Vincristine 1.5 mg/m2 - week - 1,2,3,4,5,6,7,8,9,10,12,15,18 19400
CM0107-b : WILMS TUMOR - Dactinomycin, Vincristine & Adriamycin ; Dactinomycin 1.35 mg /m2 - week - 0, 6, 12, 18,24 ; Adriyamycin 30-45 mg /m2- week - 3, 9, 15, 21 ; Vincristine 2mg max- week - 1,2,3,4,5,6,7,8,9,10,12,15,18,21,24 23200
CM0107-c : WILMS TUMOR - Adriamycin, Cyclophosphamide, Etoposide, Vincristine ; Cyclophosphamide 440mg/m2/day - week 3, 9, 15, 21 for 5 days, week - 6,12,18,24 for 3 days ; Adriyamycin 30-45mg /m2- week -0, 6, 12, 18,24 ; Vincristine 2mg (max)- week - 1,2,4,5,6,7,8,10,11, 12,13,18,24 ; Etoposide 100mg /m2- week - 3,9,15,21 53700
CM0107-d : WILMS TUMOR - Cyclophosphamide, Etoposide, Carboplatin ; Cyclophosphamide 440mg/m2/day - week 6,15,24 *5 days / week ; Carboplatin 500mg/m2 - week - 0,3,9,12,18,21 *2 days / week ; Etoposide 100mg/m2 - week - 0,3,9,12,18,21 *5 days / week 84500
CM0107-e : WILMS TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0108-a : HEPATOBLASTOMA- OPERABLE - PLADO - Cisplatin + Doxorubicin ; cisplatin (PLA) (80mg/m2 / iv), doxorubicin (DO) (30 mg/m2 IV ; Every 21 days for 6 cycles 2800
CM0108-b : HEPATOBLASTOMA- OPERABLE - Cisplatin + Vincristine +5FU ; cisplatin (90 mg/m2), vincristine (1.5mg/m2), 5-FU(5-Flurouracil- 600 mg/m2) ; Every 21 days for 6 cycles 2400
CM0108-c : HEPATOBLASTOMA- OPERABLE - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0109-a : HEPATOCELLULAR CARCINOMA - Sorafenib ; Sorafenib 400 mg PO BID 5800
CM0109-b : HEPATOCELLULAR CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0110A : Neuroblastoma ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN 8000
CM0110B : Neuroblastoma ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300mg/m2 ; ADRIAMYCIN 60mg/m2 ; VINCRISTINE 1.5mg/m2 7100
CM0110C : Neuroblastoma ALL STAGES - Cisplatin & Etoposide ; Days 1-5 : Cisplatin - 20mg/m2 ; Days 1-5 : Etoposide - 70 mg/m2 4900
CM0110D : Neuroblastoma ALL STAGES - Carboplatin & Etoposide ; Days 1-2 : Carboplatin - 500mg/m2 ; Days 1-5: Etoposide 100mg/m2 6500
CM0110E : Neuroblastoma ALL STAGES - For Stage IV Palliative Chemotherapy only 10000
CM0110F : Neuroblastoma ALL STAGES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0111-a : RETINOBLASTOMA - Melphalan - Intra-arterial ; Melphalan - 3-7.5mg - Intra-arterial 9700
CM0111-b : RETINOBLASTOMA - Carboplatin - Intra-arterial ; Carboplatin 15-30 mg - Intra-arterial 8900
CM0111-c : RETINOBLASTOMA - Topotecan - Intra-arterial ; Topotecan 0.15-1.5 mg - Intra-arterial 9900
CM0111-d : RETINOBLASTOMA - Methotrexate - Intra-arterial ; Methotrexate 6-12 mg - Intra-arterial 8600
CM0111-e : RETINOBLASTOMA - Carboplatin - Peri Ocular ; Carboplatin 20mg/m2 - Peri Ocular 1900
CM0111-f : RETINOBLASTOMA - Topotecan - Peri Ocular ; Topotecan 0.09 - 0.27 - Peri Ocular 4300
CM0111-g : RETINOBLASTOMA - Melphalan - Intra-vitreal ; Melphalan 20-30 mcg / 0.1cc - Intra-vitreal 270
CM0111-h : RETINOBLASTOMA - Carboplatin - Intra-vitreal ; Carboplatin 3-6mcg / 0.05cc - Intra-vitreal 1900
CM0111-i : RETINOBLASTOMA - Methotrexate - Intra-vitreal ; Methotrexate 400mcg/0.1cc - Intra-vitreal 1600
CM0111-j : RETINOBLASTOMA - Carboplatin + Etoposide + Vincristine ; Carboplatin 560mg/m2 ; Etoposide 150mg/m2 ; Vincristine 1.5mg/m2 6800
CM0111-k : RETINOBLASTOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0112-a : HISTIOCYTOSIS - Prednisolone and Vinblastine - 1; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 6100
CM0112-b : HISTIOCYTOSIS - Prednisolone and Vinblastine - 2; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 6800
CM0112-c : HISTIOCYTOSIS - Prednisolone and Vinblastine - continuation; Prednisolone and Vinblastine - continuation after either course 1 or both 1 & 2 ; Prednisolone - 5 days a week oral ; Vinblastine -IV ; repeat every 3 weeks till 1 year 1800
CM0112-d : HISTIOCYTOSIS - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0113-a : RHABDOMYOSARCOMA - VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) ; Day -1 - Vincristine 1.5 mg /m2 IV (2 mg max), Doxorubicin 75 mg /m2 IV , cyclophosphamide 1200 mg /m2 IV + mesna ; Repeat at 21 day intervals for 4-6 cycles 3800
CM0113-b : RHABDOMYOSARCOMA - IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) ; Day 1,2 - Ifosfamide IV 3 g/m2 + mesna ; Day 1 - Vincristine IV 1.5 mg/m2 (max 2 mg), Actinomycin-D IV 1.5 mg/m2 (max 2 mg) ; Repeat at 21 day intervals for 6 cycles 5600
CM0113-c : RHABDOMYOSARCOMA - IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) ; Days 1 and 2 - Ifosfamide 3 g/m2 + Mesna, Doxorubicin 30mg/m2 ; Day 1 - vincristine 1.5 mg/m2, Actinomycin-D 1.5 mg/m2 ; Repeat at 21 day intervals for 6 cycles 5500
CM0113-d : RHABDOMYOSARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0114-i-a : EWINGS SARCOMA - Induction Treatment - VIDE ; Day 1:Vincristine 1.5mg/m2(max 2mg) IV ; Days 1-3:Doxorubicin 20mg/m2 IV, ifosfamide 3g/m2IV, mesna continuous IV, etoposide 150mg/m2 IV ; Repeat cycle every 3 weeks for up to 6 cycles 8300
CM0114-i-c : EWINGS SARCOMA - Induction Treatment - VAIA - 4 day Regimen ; Day 1:Vincristine 1.5mg/m2IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, then local therapy, followed by 10 additional cycles of VAIA for High risk and ; 10 additional cycles of VAIA or 10 cycles of VACA for standard-risk patients 7600
CM0114-i-d : EWINGS SARCOMA - Induction Treatment - VAIA - 24 day Regimen ; Days 1, 8, 15, and 22: Vincristine 1.5mg/m2 IV ; Days 1, 2, 22, 23, 43, and 44 : Ifosfamide 3,000mg/m2 IV + mesna ; Days 1, 2, 43, and 44 : Doxorubicin 30mg/m2 IV ; Days 22, 23, and 24: Dactinomycin 0.5mg/m2 IV ; After completion of one 9-week cycle, local therapy followed by 3 additional cycles. 17700
CM0114-ii-a : EWINGS SARCOMA - Maintenance Treatment - Etoposide/Ifosfamide ; Days 1-5: Ifosfamide 1,800mg/m2/day IV + mesna ; Days 1-5: Etoposide 100mg/m2/day IV. 8200
CM0114-iii : EWINGS SARCOMA - Maintenance Treatment - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable 10000
CM0116-a : CERVICAL CANCER - CISPLATIN ; Cisplatin 40mg/m2 IV once weekly for up to 6 cycles 1800
CM0116-b : CERVICAL CANCER - Cisplatin & 5FU with RT ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 IV over 96 hours ; Repeat cycle every 3 weeks for 3 9200
CM0116-c : CERVICAL CANCER - Cisplatin & 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV 8900
CM0116-d : CERVICAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0117-a : VULVAL CANCER - Cisplatin ; Day 1 : 40 mg/m 2 IV 1800
CM0117-b : VULVAL CANCER - Cisplatin + 5FU ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 ; Repeat cycle every 3 weeks - total 3 cycles 4700
CM0117-c : VULVAL CANCER - 5-FU + Mitomycin ; 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day continuous IV infusion ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), 11400
CM0117-d : VULVAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0118-a : VAGINAL CANCER - Cisplatin ; Cisplatin 75mg/m2 ; once weekly for up to 6 doses 1800
CM0118-b : VAGINAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0119-a : OVARIAN CANCER - Paclitaxel + Cisplatin ; Day 1: Paclitaxel 135mg/m2 continuous IV ; Day 2: Cisplatin 75-100mg/m2 ; Day 8: Paclitaxel 60mg/m2 ; Repeat every 3 weeks for 6 cycles. 8800
CM0119-b : OVARIAN CANCER - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 175mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL IV ; Repeat every 3 weeks for 6 cycles 7000
CM0119-c : OVARIAN CANCER - Docetaxel + Carboplatin ; Day 1: Docetaxel 60-75mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL ; Repeat every 3 weeks for 6 cycles 8700
CM0119-d : OVARIAN CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only) 10000
CM0121-a : OVARY- GERM CELL TUMOR - BEP (Bleomycin + Etoposide + Cisplatin) ; Days 1,8,15 : Bleomycin 30 units/wk IV, Etoposide 100 mg/m 2/day IV ; Days 1-5 : Cisplatin 20 mg/m 2/day IV ; Repeat every 21 days 3-4 cycles 10800
CM0121-b : OVARY- GERM CELL TUMOR - EP ( Etoposide + Carboplatin) ; Day 1 : Carboplatin 400 mg/m 2 IV on days 1-3 ; Repeat every 28 days for three cycles 6500
CM0121-c : OVARY- GERM CELL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0122-a : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (5 days regimen) ; Days 1-5: MTX 0.4 mg/kg/day IV or IM for 5 days, not to exceed 25 mg/day ; Repeat cycle every 14 days 2100
CM0122-b : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (8-day alternating regimen) ; Days 1, 3, 5, and 7 : MTX 1 mg/kg IM, ; Days 2, 4, 6, and 8 : Folinic acid 15 mg ; Repeat cycle every 14 days 2900
CM0122-c : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate + Folinic Acid ; Day 1 : MTX 100 mg/m 2 IVP, then 200 mg/m 2 infusion ; Day 2 : Folinic acid 15 mg IM/PO q12h for 4 doses ; Repeat cycle every 18 days 2000
CM0122-d : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate - Weekly ; MTX 30-50 mg/m 2 IM weekly 1300
CM0122-e : GESTATIONAL TROPHOBLAST DISEASES - Act-D ; Act-D 10-13 mcg/kg or 0.5-mg flat dose IV qd for 5d ; Repeat cycle every 14 days 7800
CM0122-f : GESTATIONAL TROPHOBLAST DISEASES - Actinomycin ; Actinomycin 1.25 mg/m 2 IV ; Repeat every 2 weeks 2200
CM0122-g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (complete) ; Day 1 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, MTX - 300 mg/m2 IV ; Day 2 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, Leucovorin - 15 mg PO/IM q12h 4 doses ; Day 8 : Vincristine - 0.8 mg/m2 IV, Cyclophosphamide - 600 mg/m2 IV ; Repeat cycle every 14 days 6400
CM0122-h : GESTATIONAL TROPHOBLAST DISEASES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0123-a : TESTICULAR CANCER - EP ; Days 1-5: Etoposide 100mg/m2, cisplatin 20mg/m2 ; Repeat cycle every 3 weeks for 4 cycles. 5400
CM0123-b : TESTICULAR CANCER - BEP ; Days 1-5: Cisplatin 20mg/m2, etoposide 100mg/m2 ; Days 1, 8, and 15 OR Days 2, 9, or 16: Bleomycin 30 units IV ; Repeat cycle every 3 weeks for 3 cycles. 10000
CM0123-c : TESTICULAR CANCER - VIP ; Day 1 (before ifosfamide): Mesna 120mg/m2 IV ; Days 1-5: Etoposide 75mg/m2 IV, mesna 1,200mg/m2 IV, ifosfamide 1,200mg/m2 IV + cisplatin 20mg/m2. ; Repeat cycle every 3 weeks for 4 cycles. 6300
CM0123-d : TESTICULAR CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0124-a : PROSTATE CANCER - Docetaxel + prednisone ; Day 1: Docetaxel 75mg/m2 IV, prednisone 5mg orally twice daily. ; once every 3 weeks, Repeat for up to 10 cycles if tolerated 3600
CM0124-b : PROSTATE CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0125-a : FEBRILE NEUTROPENIA - First-line monotherapy ; Piperacillin-tazobactam 4.5 g ; Cefepime 2 g ; Meropenem 1 g ; Imipenem-cilastatin 500 mg 13500
CM0125-b : FEBRILE NEUTROPENIA - Second-line dual therapy ; Piperacillin-tazobactam 4.5 g IV plus an aminoglycoside ; Meropenem 1 g IV plus an aminoglycoside ; Imipenem-cilastatin 500 mg IV plus an aminoglycoside 19500
CM0125-c : Other Regimen 10000
CM0126-a : THYROID CANCER - sorafenib ; sorafenib 400 mg PO BID 2900
CM0126-b : THYROID CANCER - sunitinib ; sunitinib 50 mg 28500
CM0126-c : THYROID CANCER - pazopanib 9500
CM0126-d : THYROID CANCER - Doxorubicin ; Doxorubicin 60 mg/m2 as monotherapy or in combination with cisplatin 40 mg/m2 4400
CM0126-e : THYROID CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0127-a : THYMOMA - CAP ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 50mg/m2 IV, cyclophosphamide 500mg/m2 IV. ; Repeat every 21 days for a max of 8 cycles. 4600
CM0127-b : THYMOMA - CAPP ; Day 1: Cyclophosphamide 500mg/m2 IV ; Days 1-3: Cisplatin 30mg/m2 IV ; Days 1-3: Doxorubicin 20mg/m2 ; Days 1-5: Prednisone 100mg. ; Repeat every 3 weeks for 3 cycles. 6800
CM0127-c : THYMOMA - ADOC ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 40mg/m2 IV ; Day 3: Vincristine 0.6mg/m2 IV ; Day 4: Cyclophosphamide 700mg/m2 IV. ; Repeat every 3 weeks for 5 cycles. 5900
CM0127-d : THYMOMA - PE ; Day 1: Cisplatin 60mg/m2 IV ; Days 1-3: Etoposide 120mg/m2 IV ; Repeat every 3 weeks for a max of 8 cycles. 5100
CM0127-e : THYMOMA - VIP ; Days 1-4: Etoposide 75mg/m2 IV, ifosfamide 1.2g/m2 IV, cisplatin 20mg/m2 IV. ; Repeat every 3 weeks for 4 cycles 7600
CM0127-f : THYMOMA - Carboplatin+paclitaxel ; Day 1: Paclitaxel 225mg/m2 IV, carboplatin AUC = 6 IV ; Repeat every 3 weeks for a max of 6 cycles. 9300
CM0127-g : THYMOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0128-i-a : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Combination PCV (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally. ; Days 8-21: Procarbazine 60mg/m2 orally once daily. ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. 3800
CM0128-i-b : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (7 weeks) ; Days 1-49: Temozolomide 75mg/m2 orally. ; Repeat cycle every 11 weeks (7 weeks on/4 weeks off) for 6 cycles. 6500
CM0128-i-c : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide monthly 5-day course ; Temozolomide monthly 5-day courses at doses of 180 - 200mg/m2/day 2100
CM0128-i-d : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (3 weeks) ; Days 1-21: Temozolomide 75mg/m2/day orally. ; Repeat cycle every 28 days. 3400
CM0128-ii-a : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Temozolomide monthly 5-day course ; Days 1-5: Temozolomide 200mg/m2/day orally. ; Repeat cycle every 4 weeks until disease progression or for up to 24 cycles. 2100
CM0128-ii-b : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV with deferred RT (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks 3800
CM0128-ii-d : Adjuvant Temozolomide 2100
CM0128-ii-e : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV for 1p19q co-deleted (with Radiotherapy) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. for 6 cycles 3800
CM0128-iii-a : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) 7200
CM0128-iii-b : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Adjuvant Temozolomide (preceeded by Concurrent temozolzmide) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days for 6 cycles. 2100
CM0128-iii-c : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (post RT) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days 2100
CM0128-iii-d : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (200mg) with standard RT ; Days 1-5: Temozolomide 200mg/m2, orally 2100
CM0128-iv-a : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + lomustine ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; ; During Cranio-spinal RT 4400
CM0128-iv-b : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV. 5500
CM0128-v-a-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + Cytarabine ; Day 1: MTX 3.5g/m2 ; Days 2-3: Cytarabine 2g/m2 IV twice a day. 6600
CM0128-v-a-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + leucovorin + Ifosfamide + mesna ; Day 1: MTX 4gm/m2 IV, ; Days 2-5: leucovorin 20-25mg IV (upto 40mg) ; Days 3-5: Ifosfamide 1.5gm/m2 IV + mesna 400mg IV 9500
CM0128-v-b-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + MTX + vincristine +procarbazine ; Day 1: Rituximab 500mg/m2 IV ; Day 2: MTX 3.5mg/m2 IV plus vincristine 1.4mg/m2 ; Procarbazine 100mg/m2/day administered for 7 days with odd-numbered cycles 41900
CM0128-v-c-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Induction ; MTX 8g/m2 IV ; Repeat every 2 weeks until complete response achieved or max of 8 cycles reached. ; 7900
CM0128-v-c-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Consolidation ; MTX 8g/m2 IV administered ; Repeat every 2 weeks for 2 cycles. 7900
CM0128-v-c-3-i : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (Cycles 1-4) ; Day 1: MTX 8g/m2 IV, Rituximab 375mg/m2 IV. ; Repeat every 4 weeks for 4 cycles 32400
CM0128-v-c-3-ii : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (cycles 5-11) ; MTX 8g/m2 IV administered every 4 weeks for 11 cycles. ; Repeat cycle every 4 weeks for 4 cycles 7900
CM0128-v-d-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - Induction ; Day 1: Rituximab 375mg/m2 IV, followed by ; Days 1-5: Temozolomide 150-200mg/m2 orally daily, after rituximab infusion. ; Repeat cycle every 4 weeks for 4 cycles. 26600
CM0128-v-d-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - MaintananceDays 1-5: Temozolomide 150-200mg/m2 orally daily. ; Repeat cycle every 4 weeks for 8 cycles. 1600
CM0128-v-e-1 : BRAIN CARCINOMA - Meningioma - Interferon-alfaInterferon-alfa ; alpha-IFN 106 units/m2 SC every other day for 4 weeks. ; Repeat cycle every 4 weeks. ; 6000
CM0128-v-e-2 : BRAIN CARCINOMA - Meningioma -Somatostatin analog ; Sandostatin LAR Depot 10-30mg IM ; Repeat every 4 weeks. ; 5400
CM0128-v-e-3 : BRAIN CARCINOMA - Meningioma - Sunitinib ; Days 1-28: Sunitinib 50mg orally daily. ; Repeat cycle every 42 days. 2900
CM0129-i-a : HEAD AND NECK CANCER - HIgh Dose Cisplatin ; Cisplatin 100mg/m2 IV + concurrent radiotherapy; Repeat cycle every 3 weeks for 3 cycles 2000
CM0129-i-b : HEAD AND NECK CANCER - Carboplatin + infusional 5-FU ; Days 1-4: 5-FU 600mg/m2/day as continuous IV I, carboplatin 70mg/m2/day IV ; Repeat every 3 weeks for 3 cycles (given concurrently with radiotherapy). 4700
CM0129-i-c : HEAD AND NECK CANCER - 5-FU + hydroxyurea ; Day 1: Hydroxyurea 1,000mg orally every 12 hours (11 doses/cycle), 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy 2300
CM0129-i-d : HEAD AND NECK CANCER - Cisplatin + paclitaxel ; Day 1: Paclitaxel 30mg/m2 IV (every Monday), ; Day 2: Cisplatin 20mg/m2 IV (every Tuesday). ; Repeat cycle every week for 7 cycles, with Concurrent radiotherapy 3400
CM0129-i-e : HEAD AND NECK CANCER - Cisplatin + infusional 5-FU ; Day 1: Cisplatin 60mg/m2 over ; Days 1-5: 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy 5300
CM0129-i-f : HEAD AND NECK CANCER - Carboplatin + paclitaxel ; Day 1: Paclitaxel 40-45mg/m2, carboplatin 100mg/m2 ; Repeat cycle every week for 8 cycles, with Concurrent radiotherapy 3500
CM0129-i-g : HEAD AND NECK CANCER - Weekly cisplatin ; Cisplatin 40mg/m2 IV per week 1800
CM0129-i-h : HEAD AND NECK CANCER - Cisplatin (For high risk oropharyngeal carcinoma) ; Days 1, 22, and 43: Cisplatin 100mg/m2 IV + radiotherapy. 5300
CM0129-i-i : HEAD AND NECK CANCER - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV, ; Days 1-5: 5-FU 750mg/m2/day IV. ; Repeat every 3 weeks for up to 4 cycles. 6700
CM0129-i-j : HEAD AND NECK CANCER - Paclitaxel + cisplatin+ infusional 5-FU ; Day 1: Paclitaxel 175mg/m2 ; Day 2: Cisplatin 100mg/m2 ; Day 2-6: 5-FU 500mg/m2/day IV ; Repeat every 3 weeks for 3 cycles. 7900
CM0129-ii-a-1 : Nasopharynx Cancer - Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) ; Day 1: Cisplatin 100mg/m2 IV; plus radiotherapy. ; Repeat cycle every 3 weeks for 3 cycles; followed by concurrent Cisplatin +5FU 2000
CM0129-ii-a-2 : Nasopharynx Cancer - concurrent Cisplatin +5FU - Preceeded by (Concurrent Cisplatin 3 cycles) ; Days 1-4: Cisplatin 80mg/m2/day, 5-FU 1,000mg/m2/day IV ; Repeat cycle every 4 weeks for 3 cycles 6700
CM0129-ii-b-1 : Nasopharynx Cancer - Concurrent Carboplatin - (followed by concurrent Carboplatin +5FU) ; Day 1: Carboplatin AUC 6mg/min/mL IV. ; Repeat cycle every 3 weeks for 3 cycles; 4300
CM0129-ii-b-2 : Nasopharynx Cancer - concurrent Carboplatin +5FU - Preceeded by (Concurrent Carboplatin ) ; Day 1: Carboplatin AUC 5mg/min/mL IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. 13500
CM0129-ii-c : Nasopharynx Cancer - Concurrent Cisplatin ; Cisplatin 40mg/m2 ; Repeat weekly for 7 cycles 1800
CM0129-ii-d-1 : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU - followed by Cisplatin after 3 cycles ; Day 1: Docetaxel 70mg/m2 IV, cisplatin 75mg/m2 IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat every week for 3 cycles 6200
CM0129-ii-d-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 3 cycles of Docetaxel + 5-FU ; Day 1: Cisplatin 100mg/m2; ; Repeat every 3 weeks, Till radiation 2800
CM0129-ii-e-1 : Nasopharynx Cancer - Docetaxel + cisplatin - followed by Cisplatin after 2 cycles ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV ; Repeat every 3 weeks for two cycles 3900
CM0129-ii-e-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 2 cycles of Docetaxel + cisplatin ; Cisplatin 40mg/m2 IV ; weekly concurrent with radiotherapy. 2300
CM0129-ii-f : Nasopharynx Cancer - Cisplatin + 5-FU ; Day 1: Cisplatin 100mg/m2/day IV. ; Days 1-4: 5-FU 1,000mg/m2/day continuous IV infusion for 4 days. ; Repeat cycle every 3 weeks for a minimum of 6 cycles 5100
CM0129-iii : HEAD AND NECK CANCER (or) Nasopharynx Cancer - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0130-a : Pazopanib 19000
CM0130-b : Sunitinib 29000
CM0130-c : Sorafenib 5800
CM0130-d : Other Regimen 10000
CM0131-i-a : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin + etoposide ; Day 1: Paclitaxel 200 mg/m 2 IV, carboplatin AUC 6 ; Days 1-10: etoposide 50 mg PO alternating with 100 mg daily ; Repeat every 21days for 2-3 cycles; restage, can be treated upto 8 cycles 8000
CM0131-i-b : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin ; Day 1: Paclitaxel 200 mg/m 2, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles 7200
CM0131-i-c : UNKNOWN PRIMARY - Adenocarcinoma - Docetaxel + carboplatin ; Day 1: Docetaxel 65mg/m2 IV, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles. 3800
CM0131-i-d : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + cisplatin ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat cycle every 3 weeks for 4 cycles. 5300
CM0131-i-e : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + docetaxel ; Day 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes ; Day 8: Docetaxel 75mg/m2 IV ; Repeat cycle every 3 weeks for a maximum of 6 cycles 5800
CM0131-i-f : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + irinotecan ; Days 1 and 8: Irinotecan 100mg/m2 IV, gemcitabine 1000mg/m2 IV. ; Repeat cycle every 3 weeks for 6 cycles.restage every 2-3 cycles 5600
CM0131-ii-a : UNKNOWN PRIMARY - Squamous cell carcinoma - Paclitaxel + cisplatin + 5-FU ; Paclitaxel 175 mg/m 2 IV, ; Day 2: cisplatin 100 mg/m 2 IV, ; Day 5-FU (5-fluorouracil) 500 mg/m 2/day IV ; Repeat every 21d 6200
CM0131-ii-b : UNKNOWN PRIMARY - Squamous cell carcinoma - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Days 1-5: 5-FU 750mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. 6800
CM0131-iii-b : UNKNOWN PRIMARY - Neuroendocrine tumors - Etoposide + cisplatin ; Days 1-3: Etoposide 100 mg/m 2 ; Days 2-3: cisplatin 45 mg/m 2 IV ; Repeat every 28 days 5000
CM0131-iv : UNKNOWN PRIMARY - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0132-a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Gemcitabine + cisplatin ; Days 1 and 8: Cisplatin 25mg/m2 IV, gemcitabine 1,000mg/m2 IV ; Repeat every 21 days for 4 cycles, re-evaluate and continue an additional 4 cycles if warranted 3700
CM0132-b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV 4100
CM0132-c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Capecitabine ; Capecitabine oral ; Repeat every 21 days 3600
CM0132-d : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0133-i-a : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV ; Repeat every 4 weeks for six cycles 6600
CM0133-ii-a : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - 5-FU + Leucovorin ; Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2 IV ; Repeat cycle every 4 weeks 5000
CM0133-ii-b : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Gemcitabine & 5FU ; Prior to chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 4 weeks for 3 months. 6700
CM0133-ii-c : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Continuous infusion 5-FU (with Radiation) ; Prior to chemoradiation: ; Days 1-21: 5-FU 250mg/m2/day continuous IV infusion; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1-28: 5-FU 250mg/m2/day continuous IV infusion; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 6 weeks for 3 months. 20700
CM0133-iii-a : PANCREAS CARCINOMA - Neoadjuvant therapy - CapecitabineCapecitabine ; Capecitabine ; Repeat cycle every 3 weeks for up to 52 weeks. 3600
CM0133-iv : PANCREAS CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0134-a : PERI AMPULLARY CARCINOMA - 5-FU ; Fluorouracil 425 mg/m2 administered on days 1 to 5 and 29-33 5300
CM0134-b : PERI AMPULLARY CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0135-b : NEURO ENDOCRINE CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0136-i-a : SARCOMA - Gastrointestinal Stromal Tumor - GIST - Imatinib ; Imatinib 400mg orally once daily to twice daily 3000
CM0136-ii-a : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + dacarbazine (AD) ; Days 1-4: Doxorubicin 60mg/m2 + dacarbazine 750mg/m2 ; Repeat cycle every 3 weeks 11500
CM0136-ii-b : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + ifosfamide + mesna ; Days 1 and 2: Doxorubicin 30mg/m2/day IV, ifosfamide 3,750mg/m2/day IV, mesna 750mg/m2 IV ; Repeat cycle every 3 weeks 9200
CM0136-ii-c : SARCOMA - SOFT TISSUE SARCOMA - Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) ; Days 1-3: Doxorubicin 20mg/m2/day, ifosfamide 2,500mg/m2/day, dacarbazine 300mg/m2/day IV ; Days 1-4: Mesna 2,500mg/m2/day IV for 84 to 96 hours. ; Repeat cycle every 3 weeks. 10700
CM0136-ii-d : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide + epirubicin + mesna ; Days 1 and 2: Epirubicin 60mg/m2/day IV ; Days 1-5: Ifosfamide 1.8g/m2/day IV + mesna. ; Repeat cycle every 3 weeks for 5 cycles. 12800
CM0136-ii-e : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + docetaxel ; Days 1 and 8: Gemcitabine 900mg/m2 IV ; Day 8: Docetaxel 100mg/m2 IV. ; Repeat cycle every 3 weeks 5100
CM0136-ii-f : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + vinorelbine ; Days 1 and 8: Vinorelbine 25mg/m2 IV, gemcitabine 800mg/m2 IV ; Repeat cycle every 3 weeks 14700
CM0136-ii-g : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + dacarbazine ; Day 1: Gemcitabine 1,800mg/m2 IV + dacarbazine 500mg/m2 IV. ; Repeat cycle ever 2 weeks for a total of 12 cycles; 3300
CM0136-ii-h : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin ; Doxorubicin 60-75mg/m2 IV ; once every 3 weeks 2900
CM0136-ii-i : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Days 1-3: Ifosfamide 2,000-3,000mg/m2/day IV for 3 to 4 days + mesna ; Repeat every 3 weeks. 10000
CM0136-ii-j : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Day 1: Ifosfamide 5,000mg/m2 + mesna 5,000mg/m2 IV ; Day 2: mesna 400-600mg/m2 IV ; Ifosfamide, mesna ; Repeat every 3 weeks 1900
CM0136-ii-k : SARCOMA - SOFT TISSUE SARCOMA - Epirubicin ; Epirubicin 160mg/m2 IV ; Repeat every 3 weeks 5900
CM0136-ii-l : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine ; Days 1 and 8: Gemcitabine 1,200mg/m2 IV ; Repeat cycle every 3 weeks. 3600
CM0136-ii-m : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (i) ; Dacarbazine 250mg/m2/day IV for 5 days ; Repeat every 3 weeks. 6200
CM0136-ii-n : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (ii) ; Dacarbazine 800-1,000mg/m2 IV ; Repeat every 3 weeks. 2400
CM0136-ii-o : SARCOMA - SOFT TISSUE SARCOMA - Liposomal doxorubicin ; Liposomal doxorubicin 30-50mg/m2 IV ; Repeat every 4 weeks. 7900
CM0136-ii-p : SARCOMA - SOFT TISSUE SARCOMA - Temozolomide ; Temozolomide 200mg/m2 orally twice daily for 5 days, followed by 9 doses of 90mg/m2 orally ; Repeat every 4 weeks 4200
CM0136-iii : SARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0137-a : PRIMITIVE NEURO ECTODERMAL TUMOR - Weekly vincristine ; vincristine 1.5mg/m2 IV, max 2mg ; for 5 to 6 weeks 1700
CM0137-b : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + lomustine ; During craniospinal radiotherapy (RT) ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; up to max 8 doses 4400
CM0137-c : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV, max 2mg ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV 7600
CM0137-d : PRIMITIVE NEURO ECTODERMAL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0137-vi : Other Regimen 10000
CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy 10000
CM0139-a : ANAL CANAL CANCER - 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day IV ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), with Concurrent radiotherapy 11400
CM0139-b : ANAL CANAL CANCER - Capecitabine + Mitomycin (i) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus, with Concurrent radiotherapy. 8100
CM0139-c : ANAL CANAL CANCER - Capecitabine + Mitomycin (ii) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Day 1: Mitomycin 12mg/m2 IV bolus, with Concurrent radiotherapy 6800
CM0139-d : ANAL CANAL CANCER - Cisplatin + 5-FU ; Days 1-5: 5-FU 1,000mg/m2/day IV ; Day 2: Cisplatin 100mg/m2 IV ; Repeat cycle every 4 weeks, with Concurrent radiotherapy 6700
CM0139-e : ANAL CANAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0183 : SURGICAL CORRECTION OF LONGBONE FRACTURE-FRACTURE NECK/ SHAFT OF FEMUR/FRACTURE SHAFT OF OTHER LONG BONES (HUMERUS,BOTH BONES OF FOREARM, BOTH BONES OF LEG) 20025
CM0184 : CORRECTION OF NON-UNION FRACTURES - NON-UNION OF FRACTURE OF FEMUR/BOTH BONE OF LEG/ NON-UNION OF OTHER LONG BONES -HUMERUS/ BOTH BONES OF FOREARM WITH OR WITHOUT BONE GRAFTING 20025
CM0185 : SKELETAL SKULL TRACTION 27315
CM0186A : IMPLANT EXIT- K-WIRES /SCREWS/OTHER MINOR IMPLANTS 6975
CM0186B : IMPLANT EXIT- PLATES (SPINE IMPLANTS/OTHER MAJOR IMPLANT) 18450
CM0187 : ARTHRODESIS OF JOINTS -SHOULDER/ HIP / KNEE /ELBOW/ ANKLE / WRIST / HAND / FOOT 24300
CM0192 : ILIZAROV RING FIXATOR APPLICATION-FEMUR - DEFORMITY CORRECTION / LIMB LENGTHENING/TIBIA - DEFORMITY CORRECTION / LIMB LENGTHENING /PLATING/EXTERNAL FIXATOR/K WIRES 35775
CM0193 : SURGERY FOR NEGLECTED CTEV/RECURRENT CTEV-CTEV CORRECTIVE SURGERY /CTEV PONSETTI CORRECTION (FOLLOW UP PROCEDURES)/CTEV ILIZAROV 40275
CM0195 : KNEE LIGAMENT RECONSTRUCTION-ACL RECONSTRUCTION/PCL RECONSTRUCTION/MPFL RECONSTRUCTION 27000
CM0203 : SURGICAL CORRECTION FOR PELVIC BONE FRACTURES 29025
CM0204 : CORRECTION SACRO ILLIAC JOINT / ACETABULAR FRACTURES 26550
CM0336 : D V T - IVC FILTER 65115
CM0337 : PERIPHERAL EMBOLECTOMY WITHOUT GRAFT 24750
CM0338 : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL 35775
CM0339 : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE 66600
CM0340 : ARTERIAL EMBOLECTOMY 25425
CM0341 : VASCULAR TUMORS 35595
CM0342 : SMALL ARTERIAL ANEURYSMS - REPAIR 17100
CM0343 : MEDIUM SIZE ARTERIAL ANEURYSMS - REPAIR 41850
CM0344 : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT 66150
CM0345 : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION 62325
CM0346 : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR 41175
CM0347A : AORTO - BILLIAC - BIFEMORAL BYPASS WITH VEIN 71325
CM0347B : AORTO - BILLIAC - BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 83475
CM0348 : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 84825
CM0349 : FEMORO DISTAL BYPASS WITH VEIN GRAFT 50625
CM0350 : FEMORO DISTAL BYPASS WITH SYNTHETIC GRAFT 70875
CM0351 : AXILLO BRACHIAL BYPASS USING SYNTHETIC GRAFT 56025
CM0352 : BRACHIO - RADIAL BYPASS WITH SYNTHETIC GRAFT 42975
CM0353 : FEMORO- POPLITEAL BYPASS WITH GRAFT 50175
CM0354 : FEMORO- POPLITEAL BYPASS WITHOUT GRAFT 27225
CM0355 : FEMORO ILEAL BYPASS WITH GRAFT 40725
CM0356 : FEMORO ILEAL BYPASS WITHOUT GRAFT 20925
CM0357 : FEMORO FEMORAL BYPASS WITH GRAFT 40275
CM0358 : FEMORO FEMORAL BYPASS WITHOUT GRAFT 21825
CM0359 : AORTO RENAL BYPASS 44775
CM0360 : AORTO MESENTRIC BYPASS 44775
CM0361 : CAROTID SUBCLAVIAN ARTERY BYPASS WITH SYNTHETIC GRAFT 66825
CM0362 : AXILLO AXILLARY BYPASS WITH SYNTHETIC GRAFT 46125
CM0363 : SUBCLAVIAN SUBCLAVIAN BYPASS WITH SYNTHETIC GRAFT 47025
CM0364 : CAROTID BODY TUMOR - EXCISION 38970
CM0365 : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT 83025
CM0366 : SURGERY WITHOUT GRAFT FOR ARTERIAL INJURIES OR VENOUS INJURIES 9675
CM0367 : VASCULAR INJURY IN UPPER LIMBS - AXILLARY, BRANCHIAL, RADIAL AND ULNAR - REPAIR WITH VEIN GRAFT 30600
CM0368 : MAJOR VASCULAR INJURY -REPAIR - LOWER LIMBS(INCLUDING FOOT) 37575
CM0369 : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (INCLUDING FOOT) 16425
CM0370 : SURGERY WITH VEIN GRAFT 14850
CM0371 : WITH PROSTHETIC GRAFT 36000
CM0372 : NECK VASCULAR INJURY - CAROTID VESSELS 81675
CM0373 : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS 81675
CM0374 : THORACIC VASCULAR INJURIES 81675
CM0375 : VARICOSE VEINS RFA FOR B/L 33750
CM0376 : COVERED STENT PLACEMENT FOR ANEURSYM / MURAL THROMBOSIS- Aorto-illiac 129375
CM0377A : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (CATHETER DIRECTED THROMBOLYSIS) - STK 44775
CM0377B : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (CATHETER DIRECTED THROMBOLYSIS) - RTPA 65475
CM0378 : BRACHIO - BASILIC TRANSPOSITION FOR HEMODIALYSIS ACCESS 19800
CM0379 : VERTEBRAL ARTERY STENTING WITH EMBOLIC PROTECTION DEVICE 63675
CM0380A : END ARTERECTOMY FOR PERIPHERAL ARTERIES 31500
CM0380B : END ARTERECTOMY FOR PERIPHERAL ARTERIES / PATCH CLOSURE 36000
CM0381 : END ARTERECTOMY FOR LARGE ARTERIES 44775
CM0382 : THROMBIN INJECTION UNDER DUPLEX GUIDANCE FOR PSEUDOANEURYSM 17100
CM0383 : PSEUDOANEURYSM MANAGEMENT WITH USG COMPRESSION THERAPY 8775
CM0384 : PSEUDOANEURYSM LIGATION 31275
CM0385 : PROFUNDA PLASTY 27225
CM0388 : SYSTEMIC THROMBOLYSIS IN PERIPHERAL ARTERY DISEASE 13500
CM0389A : REDO BYPASS AFTER GRAFT THROMBOSIS - VEIN GRAFT 44775
CM0389B : REDO BYPASS AFTER GRAFT THROMBOSIS - SYNTHETIC GRAFT 51075
CM0390A : ENDOVASCULAR AORTIC REPAIR - WITHOUT PATCH 56700
CM0390B : ENDOVASCULAR AORTIC REPAIR - WITH PATCH 88425
CM0391A : THORACIC ENDOVASCULAR AORTIC REPAIR - WITHOUT PATCH 82575
CM0391B : THORACIC ENDOVASCULAR AORTIC REPAIR - WITH PATCH 107325
CM0392 : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL 137700
CM0393 : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL 175950
CM0394 : TUMOR RESECTION WITH VASCULAR RECONSTRUCTION 60345
CM0395 : GRAFT THROMBECTOMY BYPASS / AV ACCESS SURGERY 19125
CM0396 : SARTORIUS/ GRACILIS MUSCLE FLAP COVER FOR VASCULAR COVER 26325
CM0471 : ECLAMPSIA WITH COMPLICATIONS REQUIRING VENTILATORY SUPPORT 24975
CM0472 : ECLAMPSIA WITH COMPLICATIONS & HELLP SYNDROME 20925
CM0473 : ABRUPTIO-PLACENTA WITH OUT COAGULATION DEFECTS (DIC) 17595
CM0474 : ABRUPTIO-PLACENTA WITH COAGULATION DEFECTS (DIC) 22995
CM0477 : SLINGS WITH MESH REPAIR FOR PROLAPSE 16245
CM0478A : VAULT PROLAPSE ABDOMINAL REPAIR WITHOUT MESH 14445
CM0478B : VAULT PROLAPSE ABDOMINAL REPAIR WITH MESH 15345
CM0480 : LAPAROSCOPIC MYOMECTOMY 18945
CM0481 A : RECANALISATION ANY TYPE- open 13095
CM0481 B : RECANALISATION ANY TYPE- lap 17145
CM0482 : STAGING LAPROTOMY FOR OVARIAN AND UTERINE CA 24300
CM0484 : LAPAROSCOPIC SLING OPERATIONS 21195
CM0485A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY 17145
CM0485B : PPH SURGICAL MANAGEMENT -LIGATION/ EMBOLIZATION 14445
CM0501 : ACUTE BRONCHITIS AND PNEUMONIA WITH RESPIRATORY FAILURE 36000
CM0502 : REQUIRING VENTILATORY SUPPORT -OP POISIONING / METABOLIC COMA/SCORPION STING/ SNAKE BITE / BITES & STINGS - MAX 7 DAYS 28350
CM0512 : RAPIDLY PROGRESSIVE RENAL FAILURE (RPRF) 32711
CM0513 : MAINTANENCE HEMODIALYSIS FOR CRF (8 DIALYSIS) INCLUDING SEROPOSITIVE 8000
CM0514 : PERITONEAL DIALYSIS/CAPD 12080
CM0515 : CHRONIC INFLAMMATORY DEMYELINATING POLY NEUROPATHY 13095
CM0516A : HEMORRHAGIC STROKE 27000
CM0516B : ISCHEMIC STROKE 16200
CM0547A : RT. HEPATECTOMY. 57150
CM0547B : NON ANATOMICAL RESECTION OF LIVER 36000
CM0548A : LT. HEPATECTOMY 57150
CM0548B : NON ANATOMICAL RESECTION OF LIVER 36000
CM0549 : SPLENORENAL ANASTOMOSIS 54000
CM0550 : SURGERY FOR BLEEDING ULCERS 36000
CM0551 : I STAGE-SUB TOTAL COLECTOMY + ILEOSTOMY 54000
CM0552 : II STAGE - J-POUCH 31500
CM0553 : III STAGE-ILEOSTOMY CLOSURE 19800
CM0554 A : HEPATICO JEJUNOSTOMY - BILIARY STRICTURE 67500
CM0554 B : HEPATICO JEJUNOSTOMY - INJURY / EXTERNAL BILIARY FISTULA MANAGEMENT 40500
CM0555A : BILIARY PANCREATITIS - CBD CALCULI - OTHER STENTS 19800
CM0555B : BILIARY PANCREATITIS - CBD CALCULI - SEMS 31500
CM0556 : REPAIR SURGERY FOR INJURIES DUE TO FB 45000
CM0557A : SURGICAL REMOVAL OF FOREIGN BODY FROM GIT (INVASIVE) 45000
CM0557B : SURGICAL REMOVAL OF FOREIGN BODY FROM GIT (NON INVASIVE ) 18000
CM0558 : GASTRO STUDY FOLLOWED BY THORACOTOMY & SURGICAL MANAGEMENT FOR OESOPHAGEAL INJURY FOR CORROSIVE INJURIES/FB 49950
CM0559 : HAEMANGIOMA SOL LIVER HEPATECTOMY + WEDGE RESECTION 36000
CM0560 : LIENORENAL SHUNT 54000
CM0563A : ANAL SPHINCTER RECONSTRUCTION 31500
CM0563B : LEVATOROPLASTY 36000
CM0564 : GRACILOPLASTY 36000
CM0565 : BILIARY PERITONITIS -EMERGENCY LAPAROTOMY 36000
CM0566 : SPLEEN SPARING DEVASCULARISATION 36000
CM0567 : LIVER SEGMENTECTOMY 40500
CM0568 : PORTOCAVAL ANASTOMOSIS 72000
CM0569 : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION 72000
CM0570 : WARREN SHUNT 54000
CM0571 : PANCREAS DIVISUM 27000
CM0573 A : CYSTOLITHOTRIPSY 12600
CM0573 B : CYSTOLITHOTRIPSY - LASER LITHOTRIPSY 15300
CM0573 C : RETROGRADE INTRARENAL SURGERY 25200
CM0574 : PERCUTANEOUS NEPHROLITHOTOMY 27900
CM0575 : EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY 18000
CM0576 : URETERO RENOSCOPIC LITHOTRIPSY 19800
CM0577 : SINGLE STAGE URETHROPLASTY FOR STRICTURE URETHRA 41400
CM0578 : BUCCAL MUCOSAL GRAFT- URETHROPLASTY 31500
CM0579 A : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - STAGE I 22500
CM0579 B : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - STAGE II 31500
CM0580 : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - RECONSTRUCTION PROCEDURE 31500
CM0581 : ANATROPHIC PEYLOLITHOTOMY FOR STAGHORN CALCULUS 40500
CM0582 A : RENAL CYST EXCISION - LAP 22500
CM0582 B : RENAL CYST EXCISION - OPEN 22500
CM0583 A : NEPHRECTOMY PYONEPHROSIS/XANTHO GRANULOMATOUS PYELONEPHRITIS - LAP 36000
CM0583 B : NEPHRECTOMY PYONEPHROSIS/XANTHO GRANULOMATOUS PYELONEPHRITIS - OPEN 36000
CM0584 : ENDOSCOPE REMOVAL OF STONE IN BLADDER 12600
CM0585 : URETERIC INJURY REPAIR 27000
CM0586 : BLADDER INJURY REPAIR 27000
CM0587 : URETERIC REIMPLANTATION 36000
CM0588 : VESICO VAGINAL FISTULA 27000
CM0589 : CLOSURE OF URETHRAL FISTULA 19800
CM0590 : OPTICAL URETHROTOMY 22500
CM0591 : PERINEAL URETHROSTOMY 18000
CM0592 : ANDERSON HYNES PYELOPLASTY 31500
CM0593 A : CAECO CYSTOPLASTY / AUGMENTATION - CYSTOPLASTY 28800
CM0593 B : BLADDER NECK INCISION (BNI) 18000
CM0594 : SUPRA PUBLIC CYSTOSTOMY 7200
CM0595 : DIVERTICULECTOMY /PERSISTENT URACHUS 18000
CM0596 : URACHAL SINUS/TUMOR / EXCISION 18000
CM0597 : INCONTINENCE URINE- (MALE)/ (FEMALE-INCLUDING CYSTOSCOPY OTIS URETHROTOMY) 13500
CM0598 : TRANSURETHRAL RESECTION OF PROSTATE (TURP) 24300
CM0599 : TURP WITH CYSTOLITHOTRIPSY 25200
CM0600 : CHORDEE CORECTION 13500
CM0615-II : CAROTID EMBOLECTOMY 43965
CM0616-II : PULMONARY EMBOLECTOMY WITH IVC FILTER 66150
CM0617-II : RENAL ANGIOPLASTY 51075
CM0618-II : VERTERBRAL ANGIOPLASTY 56475
CM0620-I : EXCISION OF TUMOR IN NASOPHARYNX( MALIGNANT) 18810
CM0624-I : WERTHEIMS / RADICAL HYSTERECTOMY 25695
CM0624-II : WERTHEIMS / RADICAL HYSTERECTOMY 25695
CM0625-I : AMPUTATIONS - FORE QUARTER / HIND QUARTER WITH OR WITHOUT HEMIPELVECTOMY 36000
CM0625-II : AMPUTATIONS - FORE QUARTER / HIND QUARTER WITH OR WITHOUT HEMIPELVECTOMY 36000
CM0626 A : DENGUE SHOCK SYNDROME -(ADULT/PAEDIATRICS) 19800
CM0626 B : DENGUE HEMORRHAGIC FEVER -(ADULT/PAEDIATRICS) 16200
CM0628-I : NEPHROSTOMY 7200
CM0628-II : NEPHROSTOMY 7200
CM0629-I : OBSCURE/ NON VARICEAL BLEED- CLIPPING / ARGON PLASMA COAGULATION/ INJECTION/CONSERVATIVE 41535
CM0629-II : OBSCURE/ NON VARICEAL BLEED- CLIPPING / ARGON PLASMA COAGULATION/ INJECTION/CONSERVATIVE 41535
CM0630 A-II : MIXED CONNECTIVE TISSUE DISEASE-(METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE/ PULSE CYCLOPHOSPHAMIDE THERAPY 14400
CM0631A-II : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY ) 10800
CM0631B-II : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY / INTERNAL ORGAN INVOLVEMENT REQUIRING INTRAVENOUS IMMUNOGLOBULIN/ MYCOPHENOLATE MOFETIL INDUCTION/MYCOPHENOLATE MOFETIL MAINTENANCE/ PNEUMOCOCCAL VACCINATION) 180000
CM0632-I : FULL THICKNESS BUCCAL MUCOSAL RESECTION & RECONSTRUCTION 37665
CM0633-I : ORBITAL EXENTERATION/ EVISCERATION WITH IMPLANT 21285
CM0635-I : OPEN PROSTATECTOMY 27000
CM0635-II : OPEN PROSTATECTOMY 27000
CM0636-I : RADICAL PROSTATECTOMY 45000
CM0636-II : RADICAL PROSTATECTOMY 45000
CM0640 : USG GUIDED MAJOR PROCEDURES ( EG. LIVER ABSCESS,POST OP COLLECTIONS)DRAINAGE PIGTAIL INSERTION 8550
CM0641A-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION Solid organs) 26100
CM0641B-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION other organs ) 22500
CM0641C-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION Solid organs) 19350
CM0641D-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION other organs) 35100
CM0642A-I : USG GUIDED MINOR PROCEDURES (FNAC & BIPOSY) 1350
CM0642B-I : USG GUIDED MINOR PROCEDURES (SINOGRAPHY) 1800
CM0642C-I : USG GUIDED MINOR PROCEDURES (TAPPING) 1350
CM0643-II : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER 85725
CM0644-II : EMBOLIZATION OF AV MALFORMATION OF PERIPHERAL EXTREMITY, CRANIOFACIAL AND VISCERAL PER SITTING 60075
CM0645-II : GASTROINTESTINAL VISCERAL ARTERIAL EMBOLIZATION IN UPPER AND LOWER GASTROINTESTINAL BLEEDING WITH MICROCATHETER 68625
CM0645-III : GASTROINTESTINAL VISCERAL ARTERIAL EMBOLIZATION IN UPPER AND LOWER GASTROINTESTINAL BLEEDING WITH MICROCATHETER 68625
CM0646-II : BRONCHIAL ARTERY EMBOLIZATION IN HEMOPTYSIS USING PVA AND MICRO CATHETER 50175
CM0647-II : EMBOLIZATION OF POSTOPERATIVE/ POST TRAUMATIC BLEEDING 73575
CM0648-II : UTERINE ARTERY EMBOLIZATION IN SEVERE MENORRHAGIA SECONDARY TO PPH/UTERINE FIBROIDS / AVM 47475
CM0649-II : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS 63225
CM0649-III : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS 63225
CM0650-II : EMBOLIZATION OF PULMONARY AV MALFORMATION 65925
CM0652-II : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA 83475
CM0653-II : PLAIN SIMPLE COILING OF ANEURYSM 42975
CM0654-II : BRAIN AVM EMBOLIZATION 87975
CM0655-II : TUMOR EMBOLIZATION 75375
CM0656-II : PERIPHERAL AVM EMBOLIZATION 69075
CM0657-II : TRANS ARTERIAL CHEMOEMBOLIZATION 82575
CM0658-II : HEAD AND NECK TUMOR EMBOLIZATION 66375
CM0659-II : PSEUDOANEURYSM EMBOLIZATION 41175
CM0660-II : PROSTATIC ARTERY EMBOLIZATION 38925
CM0663 : BALLOON RETERO GRADE VARICEAL EMBOLIZATION 51075
CM0664-II : LIVER HEMANGIOMA EMBOLIZATION 72675
CM0668-II : SUPERFICIAL FEMORAL ARTERY ANGIOPLASTY ANY STENTING 96525
CM0669-II : FISTULA SALVAGE ANGIOPLASTY 65925
CM0670-II : CAROTID ARTERY STENTING WITH EMBOLIC PROTECTION DEVICE 119475
CM0671-II : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE 99225
CM0672-II : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY 51525
CM0673-II : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT 94275
CM0674-II : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA 83925
CM0675-II : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT 83925
CM0676-II : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT 88425
CM0679-II : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA 110925
CM0680-II : PERIPHERAL ANGIOPLASTY 52425
CM0681-II : PERIPHERAL ANGIOPLASTY AND STENTING 56925
CM0682-II : SVC ANGIOPLASTY AND STENTING 94950
CM0683-II : IVC ANGIOPLASTY 57150
CM0684-II : IVC ANGIOPLASTY AND STENTING 98550
CM0685-II : BELOW KNEE ANGIOPLASTY 47925
CM0686-II : SUBCLAVIAN ANGIOPLASTY STENTING 97875
CM0687-II : RENAL ANGIOPLASTY STENTING 53775
CM0689-I : HEPATIC VEIN ANGIOPLASTY AND STENTING 47475
CM0689-III : HEPATIC VEIN ANGIOPLASTY AND STENTING 47475
CM0690-II : CENTRAL VEIN STENOSIS ANGIOPLASTY 94500
CM0692-II : ACUTE STROKE THROMBOLYSIS (R TPA ) 67725
CM0693-II : INFERIOR VENA CAVA FILTER PLACEMENT 70650
CM0694-I : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES 84105
CM0695-II : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE 101475
CM0703 : IMMUNOGLOBULIN THERAPY - HEREDITARY MOTOR SENSORY NEUROPATHIES/HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY/PLEXOPATHY (LUMBOSACRAL/ BRACHIAL)/PERIPHERAL NEUROPATHY (WITH NERVE BIOPSY) (HANSEN, NUTRITIONAL, TOXIC, INFECTIVE, IMMUNE)/CARPAL TUNNEL SYNDROME/ACUTE ENTRAPMENT/ COMPRESSIVE NEUROPATHY / GBS/DOG BITE CATEGORY III/OTHERS 200000
CM0706-I : EXCISION OF LINGUAL THYROID 18495
CM0707-II : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS 50355
CM0709 A-I : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. 40500
CM0709 A-II : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. 40500
CM0709 A-III : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. 40500
CM0709 B-I : LAP NEPHRECTOMY-RADICAL 40500
CM0709 B-II : LAP NEPHRECTOMY-RADICAL 40500
CM0709 B-III : LAP NEPHRECTOMY-RADICAL 40500
CM0710 A-I : NEPHROURETERECTOMY OPEN 36000
CM0710 A-II : NEPHROURETERECTOMY OPEN 36000
CM0710 B-I : NEPHROURETERECTOMY LAP 36000
CM0710 B-II : NEPHROURETERECTOMY LAP 36000
CM0713-I : TRACHEOSTOMY 4545
CM0714-I : THOROCOSTOMY 39060
CM0722-II : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA 18045
CM0723-I : HEAD & NECK CANCER COMPOSITE RESECTION 33615
CM0724-I : HEAD & NECK CANCER COMPOSITE RESECTION WITH RECONSTRUCTION 42165
CM0725-I : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 22185
CM0725-III : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 22185
CM0725-IV : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 22185
CM0729-II : DIAPHRAGMATIC HERNIA 36000
CM0730 A-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN 36000
CM0730 A-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN 36000
CM0730 B-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP 36000
CM0730 B-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP 36000
CM0730 C-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN 49500
CM0730 C-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN 49500
CM0730 D-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP 49500
CM0730 D-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP 49500
CM0731-I : HYPOSPADIAS 27000
CM0731-II : HYPOSPADIAS 27000
CM0732-I : EPISPADIAS 37800
CM0732-II : EPISPADIAS 37800
CM0733-I : TORSION TESTIS 22500
CM0733-II : TORSION TESTIS 22500
CM0734-I : URETEROCELE SURGERY 27000
CM0734-II : URETEROCELE SURGERY 27000
CM0735 A-I : OPEN CHOLECYSTECTOMY- RADICAL WITH OR WITHOUT CBD EXPLORATION 45000
CM0735 A-II : OPEN CHOLECYSTECTOMY- RADICAL WITH OR WITHOUT CBD EXPLORATION 45000
CM0735 B-I : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 19800
CM0735 B-II : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 19800
CM0736 A-I : LAP CHOLECYSTECTOMY- RADICAL WITH /WITHOUT CBD EXPLORATION 45000
CM0736 A-II : LAP CHOLECYSTECTOMY- RADICAL WITH /WITHOUT CBD EXPLORATION 45000
CM0736 B-I : LAP CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 19800
CM0736 B-II : LAP CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 19800
CM0737-I : LAP CHOLECYSTOSTOMY WITH /WITHOUT EXPLORATION CBD 19800
CM0737-II : LAP CHOLECYSTOSTOMY WITH /WITHOUT EXPLORATION CBD 19800
CM0738-I : OPEN CHOLECYSTOSTOMY 18000
CM0738-II : OPEN CHOLECYSTOSTOMY 18000
CM0739-I : GASTRECTOMY ANY TYPE - ANY CAUSE 35865
CM0739-II : GASTRECTOMY ANY TYPE - ANY CAUSE 35865
CM0739-III : GASTRECTOMY ANY TYPE - ANY CAUSE 35865
CM0740-I : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY 43965
CM0740-II : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY 43965
CM0740-III : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY 43965
CM0741-A : PENECTOMY- PARTIAL WITHOUT PERINEAL URETHEROSTOMY -CA 14040
CM0741-B : PENECTOMY- Total WITHOUT PERINEAL URETHEROSTOMY -CA 21915
CM0742A : PENECTOMY- PARTIAL WITH PERINEAL URETHEROSTOMY -CA 26595
CM0742B : PENECTOMY- TOTAL WITH PERINEAL URETHEROSTOMY -CA 35865
CM0743-I : ANTERIOR RESECTION 45765
CM0743-II : ANTERIOR RESECTION 45765
CM0743-III : ANTERIOR RESECTION 45765
CM0744-A-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH 22095
CM0744-A-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH 22095
CM0744-A-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH 22095
CM0744-B-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY 44145
CM0744-B-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY 44145
CM0744-B-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY 44145
CM0744-C-I : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS 67095
CM0744-C-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS 67095
CM0744-C-III : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS 67095
CM0745-I : ABDOMINOPERINIAL RESECTION 35415
CM0745-II : ABDOMINOPERINIAL RESECTION 35415
CM0745-III : ABDOMINOPERINIAL RESECTION 35415
CM0746A-I : SPLENECTOMY WITHOUT DEVASCULARISATION -TRAUMATIC 31500
CM0746A-II : SPLENECTOMY WITHOUT DEVASCULARISATION -TRAUMATIC 31500
CM0749A-I : NECK DISSECTION ANY TYPE - WITH WIDE EXCISION (INCLUDING MALIGNANCY) 27315
CM0749B-I : NECK DISSECTION ANY TYPE - WITHOUT WIDE EXCISION (INCLUDING MALIGNANCY) 18315
CM0750-A-I : NECK DISSECTION ANY TYPE - WITHOUT RECONSTRUCTION (INCLUDING MALIGNANCY) 23265
CM0750-B-I : NECK DISSECTION ANY TYPE - WITH RECONSTRUCTION (INCLUDING MALIGNANCY) 31365
CM0751-I : HEMIMANDIBULECTOMY 22635
CM0751-IV : HEMIMANDIBULECTOMY 22635
CM0752-I : MARGINAL MANDIBULECTOMY 20205
CM0752-IV : MARGINAL MANDIBULECTOMY 20205
CM0753-I : SEGMENTAL MANDIBULECTOMY 20205
CM0753-IV : SEGMENTAL MANDIBULECTOMY 20205
CM0754 : LEIOMYOMA EXCISION 10800
CM0755 : MULTI ORGAN RESECTION FOR ANY GI CANCERS 60525
CM0756 : SURGERIES FOR ENTERO CUTANEOUS FISTULA 36000
CM0757 : INCISIONAL HERNIA REPAIR WITHOUT MESH 18000
CM0758 : INCISIONAL HERNIA REPAIR WITH MESH 22500
CM0760-I : LIVER ABSCESS - OPEN DRAINAGE 16200
CM0760-II : LIVER ABSCESS - OPEN DRAINAGE 16200
CM0763A-I : RECTAL PROLAPSE - THEIRSCH WIRING 13500
CM0763A-II : RECTAL PROLAPSE - THEIRSCH WIRING 13500
CM0763B-I : RECTAL PROLAPSE - DEBULKING 23400
CM0763B-II : RECTAL PROLAPSE - DEBULKING 23400
CM0763C-I : RECTAL PROLAPSE - LAPAROSCOPIC RECTOPEXY 23400
CM0763C-II : RECTAL PROLAPSE - LAPAROSCOPIC RECTOPEXY 23400
CM0764B : SPLENECTOMY WITH DEVASCULARISATION -TRAUMATIC 34200
CM0764 : GLOSSECTOMY (TOTAL/HEMI/PARTIAL) FOR CANCER 17550
CM0765 : GLOSSECTOMY (TOTAL/HEMI/PARTIAL) WITH RECONSTRUCTION- FOR CANCER 35865
CM0766 : MAXILLECTOMY ANY TYPE -FOR CA 22500
CM0767 : PAROTIDECTOMY ANY TYPE- FOR CA 17550
CM0768 : LARYNGECTOMY ANY TYPE -FOR CA 32625
CM0769-I : LARYNGO PHARYNGO OESOPHAGECTOMY 66600
CM0770 A-I : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 37800
CM0770 A-II : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 37800
CM0770 A-III : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 37800
CM0770 B-I : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 29700
CM0770 B-II : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 29700
CM0770 B-III : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 29700
CM0771-I : WHIPPLES ANY TYPE 74250
CM0771-II : WHIPPLES ANY TYPE 74250
CM0771-III : WHIPPLES ANY TYPE 74250
CM0772A-I : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 31500
CM0772A-II : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 31500
CM0772A-III : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 31500
CM0772B-I : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 40500
CM0772B-II : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 40500
CM0772B-III : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 40500
CM0773 A-I : LAPAROSCOPIC CYSTECTOMY [PARTIAL / COMPLETE] WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 31500
CM0773 A-II : LAPAROSCOPIC CYSTECTOMY [PARTIAL / COMPLETE] WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 31500
CM0773 B-I : LAPAROSCOPIC CYSTECTOMY [RADICAL ]WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 40500
CM0773 B-II : LAPAROSCOPIC CYSTECTOMY [RADICAL ]WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 40500
CM0774 : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 18045
CM0775-I : SALPINGO OOPHORECTOMY U/L OR B/L- FOR CA 22815
CM0775-II : SALPINGO OOPHORECTOMY U/L OR B/L- FOR CA 22815
CM0776-I : MASTECTOMY ANY TYPE 18000
CM0776-II : MASTECTOMY ANY TYPE 18000
CM0777-A-I : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION 22500
CM0777-A-II : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION 22500
CM0777-B-I : MASTECTOMY ANY TYPE WITH SENTINAL NODE EXPLORATION 22500
CM0777-B-II : MASTECTOMY ANY TYPE WITH SENTINAL NODE EXPLORATION 22500
CM0778-A-I : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST -BENIGN 4410
CM0778-A-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST -BENIGN 4410
CM0778-B-I : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (MALIGNANT) 5850
CM0778-B-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (MALIGNANT) 5850
CM0785-I : METASTATECTOMY SOLITARY OR MULTIPLE - ANY CAUSE 33615
CM0785-II : METASTATECTOMY SOLITARY OR MULTIPLE - ANY CAUSE 33615
CM0786-A-I : OPERATIONS OF ADRENAL GLAND - U/L( ANY CAUSE) 22455
CM0786-A-II : OPERATIONS OF ADRENAL GLAND - U/L( ANY CAUSE) 22455
CM0786-B-I : OPERATIONS OF ADRENAL GLAND - B/L ( ANY CAUSE) 40635
CM0786-B-II : OPERATIONS OF ADRENAL GLAND - B/L ( ANY CAUSE) 40635
CM0789-I : STERNOTOMY + MEDIASTINAL DISSECTION - CA / SOL 37395
CM0795-I : PARATHYROIDECTOMY - ANY TYPE 22500
CM0796-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE 36000
CM0796-II : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE 36000
CM0796-III : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE 36000
CM0797-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE 40500
CM0797-II : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE 40500
CM0797-III : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE 40500
CM0798-I : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY 18000
CM0798-II : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY 18000
CM0798-III : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY 18000
CM0799-I : OESOPHAGOSTOMY 22500
CM0799-II : OESOPHAGOSTOMY 22500
CM0800-I : JEJUNOSTOMY / FEEDING JEJUNOSTOMY 18000
CM0800-II : JEJUNOSTOMY / FEEDING JEJUNOSTOMY 18000
CM0801-I : GASTROJEJUNOSTOMY 22500
CM0801-II : GASTROJEJUNOSTOMY 22500
CM0802-I : ILEOSTOMY 18000
CM0802-II : ILEOSTOMY 18000
CM0803 A-I : ILEOTRANSVERSE COLOSTOMY 22500
CM0803 A-II : ILEOTRANSVERSE COLOSTOMY 22500
CM0803 A-III : ILEOTRANSVERSE COLOSTOMY 22500
CM0803 B-I : COLOSTOMY 18000
CM0803 B-II : COLOSTOMY 18000
CM0803 B-III : COLOSTOMY 18000
CM0804-I : HARTMANNS PROCEDURE WITH COLOSTOMY- ANY CAUSE 40500
CM0804-II : HARTMANNS PROCEDURE WITH COLOSTOMY- ANY CAUSE 40500
CM0805-I : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY 18000
CM0805-II : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY 18000
CM0805-III : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY 18000
CM0806-I : RESECTION OF RETRO PERITONEAL TUMORS 40095
CM0806-II : RESECTION OF RETRO PERITONEAL TUMORS 40095
CM0807 : BONE RESECTION / CURRETTAGE/ CEMENTING- ANY CAUSE 27000
CM0808A : URINARY DIVERSION PROCEDURES ( INCLUDING PERCUTANEOUS / ANTEGRADE/RETROGRADE URETERIC STENTING ) 27000
CM0808B : URINARY DIVERSION PROCEDURES ( NEPHROSTOMY) 7200
CM0809 : SUPRA PUBIC CYSTOSTOMY 7200
CM0810-II : INTERCOSTAL DRAINAGE 3690
CM0811 : CRYOTHERAPY FOR ALL LESIONS 20475
CM0814-I : VASCULAR MALFORMATIONS- (INCLUDING SCLEROTHERAPY/ REDUCTION SURGERY) 23625
CM0820-I : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (except fingers, toes and small joints) 22500
CM0820-II : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (except fingers, toes and small joints) 22500
CM0820-III : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (fingers, toes and small joints) 9000
CM0821-I : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (except fingers, toes and small joints) 100000
CM0821-II : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (except fingers, toes and small joints) 100000
CM0821-III : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (fingers, toes and small joints) 50000
CM0822 A-I : SOFT TISSUE INJURY - LACERATION (SUTURING) /WOUND DEBRIDEMENT 540
CM0822 A-II : SOFT TISSUE INJURY - LACERATION (SUTURING) /WOUND DEBRIDEMENT 540
CM0822 B-I : SOFT TISSUE INJURY - DEEP WOUND [NERVE/TENDON REPAIR] 4500
CM0822 B-II : SOFT TISSUE INJURY - DEEP WOUND [NERVE/TENDON REPAIR] 4500
CM0825A : POLYTRAUMA/HEAD INJURY MINOR (only lacerations less than 10 cm) 2250
CM0825B : POLYTRAUMA/HEAD INJURY MINOR (deep / pitted wound exposing scalp/ bone requiring debridement and suturing) 6300
CM0826 : POLYTRAUMA/HEAD INJURY MAJOR (with fractures, intracranial bleeding) 22500
CM0827-I : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - NON VENTILATED 36000
CM0828-I : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - VENTILATED 45000
CM0829-I : STATUS EPILEPTICUS WITH MECHANICAL VENTILATION -(ADULT/PAEDIATRIC ) 36000
CM0829-II : STATUS EPILEPTICUS WITH MECHANICAL VENTILATION -(ADULT/PAEDIATRIC ) 36000
CM0830 : DIABETIC KETOACIDOSIS - TYPE I / TYPE II 27000
CM0831-I : CHRONIC RENAL FAILURE WITH HEMODIALYSIS/ERYTHROPOIETIN / IRON 15435
CM0831-II : CHRONIC RENAL FAILURE WITH HEMODIALYSIS/ERYTHROPOIETIN / IRON 15435
CM0832-I : ACUTE RENAL FAILURE WITHOUT HEMODIALYSIS/ERYTHROPOIETIN / IRON 8730
CM0832-II : ACUTE RENAL FAILURE WITHOUT HEMODIALYSIS/ERYTHROPOIETIN / IRON 8730
CM0833-I : ACUTE RENAL FAILURE WITH HEMODIALYSIS/ ERYTHROPOIETIN / IRON 10170
CM0833-II : ACUTE RENAL FAILURE WITH HEMODIALYSIS/ ERYTHROPOIETIN / IRON 10170
CM0834-I : ACUTE RENAL FAILURE / CRF WITH VENTILATOR CARE 24030
CM0834-II : ACUTE RENAL FAILURE / CRF WITH VENTILATOR CARE 24030
CM0835A-I : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY-SCUF & SLED 51300
CM0835A-II : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY-SCUF & SLED 51300
CM0835B-I : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY - CVVH/CVVHD 69300
CM0835B-II : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY - CVVH/CVVHD 69300
CM0836 : RENAL BIOPSY 13406
CM0837-I : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - NON VENTILATED 27000
CM0837-II : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - NON VENTILATED 27000
CM0838-I : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - WITH VENTILATORY SUPPORT 45000
CM0839-I : NEURO TUBERCULOSIS/NEUROCYSTICERCOSIS/ TUBERCULOMA 10800
CM0839-II : NEURO TUBERCULOSIS/NEUROCYSTICERCOSIS/ TUBERCULOMA 10800
CM0840 A : IDIPOPATHIC THROMBOCYTOPENIC PURPURA 36000
CM0840 B : TTP 54000
CM0841 A : ANY COAGULATION DISORDERS 45000
CM0841 B : DIC 22500
CM0843A : MULTI SYSTEM ORGAN FAILURE- ARDS WITHOUT DIC(BLOOD PRODUCTS) 66087
CM0843B : MULTI SYSTEM ORGAN FAILURE- ARDS WITH DIC(BLOOD PRODUCTS) 90387
CM0844 : ENTERIC ENCEPHALOPATHY 18198
CM0845 : LEPTOSPIROSIS WITH HEPATIC INVOLVEMENT 17910
CM0846 : SUBMERSION INJURY WITH VENTILATORY SUPPORT 24300
CM0847 : ARDS WITH VENTILATORY SUPPORT 75645
CM0848-I : RESPIRATORY FAILURE OF ANY CAUSE REQUIRING HIGH FREQUENCY VENTILATION 50580
CM0851A-II : CHEST WALL RESECTION WITHOUT RECONSTRUCTION 35865
CM0851B-II : CHEST WALL RESECTION WITH RECONSTRUCTION 47115
CM0854 A-I : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L 10800
CM0854 A-II : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L 10800
CM0854 A-III : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L 10800
CM0855 B-II : ORCHIDECTOMY /HIGH ORCHIDECTOMY B/L 13500
CM0861-II : POSTERIOR DISCECTOMY WITH OR WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY ( FOR CERVICAL COMPRESSIVE MYELOPATHY/ AT ANY LEVELS) 38835
CM0865-II : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- MICROLUMBAR 31545
CM0866-II : LAMINECTOMY AT ANY LEVEL - (INCLUDING LUMBAR LAMINECTOMY FOR LUMBAR CANAL STENOSIS)- CONVENTIONAL 22545
CM0877 : CAROTID ENDARTERECTOMY 50625
CM0878-I : PELVIC FLOOR RECONSTRUCTION WITH MESH 27675
CM0878-II : PELVIC FLOOR RECONSTRUCTION WITH MESH 27675
CM0879-I : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION 19215
CM0879-II : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION 19215
CM0880 : LAPAROSCOPIC ADHESOLYSIS 18045
CM0881 A-I : THALASSEMIA MAJOR /HAEMOGLOBINOPATHIES/ CHELATION THERAPY 108000
CM0881 B-I : SICKLE CELL ANAEMIA 4500
CM0882-I : INTERSTITAL LUNG DISEASE 26370
CM0883-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - BANDING 9180
CM0884-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - SCLEROTHERAPY 6840
CM0884-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - SCLEROTHERAPY 6840
CM0885-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - DEVASCULARISATION 36000
CM0885-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - DEVASCULARISATION 36000
CM0886-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - GLUE INJECTION 6840
CM0886-II : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - GLUE INJECTION 6840
CM0887-I : END STAGE RENAL DISEASE 12735
CM0887-II : END STAGE RENAL DISEASE 12735
CM0888-I : GULLAIN BARRE SYNDROME 90000
CM0888-II : GULLAIN BARRE SYNDROME 90000
CM0889-I : OPTIC NEURITIS 9000
CM0889-II : OPTIC NEURITIS 9000
CM0891-I : MYASTHENIA GRAVIS 13500
CM0891-II : MYASTHENIA GRAVIS 13500
CM0892 : MANAGEMENT OF COMA 27072
CM0893 : CAVERNOUS SINUS THROMBOSIS 22500
CM0894 : RHINOCEREBRAL MUCORMYCOSIS 27000
CM0895 : HYPER OSMOLAR NON-KETOTIC COMA 27000
CM0896 : OPERATION FOR HYDATID CYST OF LIVER 31500
CM0898 : COLONIC PULL THOROUGH /COLOPLASTY/ ABDOMINAL RESECTION 45000
CM0899-I : OESOPHAGECTOMY ANY TYPE INCLUDING (TRANS HIATAL / TRANS THORACIC WITH GASTRIC PULL UP) 58500
CM0899-II : OESOPHAGECTOMY ANY TYPE INCLUDING (TRANS HIATAL / TRANS THORACIC WITH GASTRIC PULL UP) 58500
CM0900 : OESOPHAGO- GASTRECTOMY 72000
CM0901 : ACHALASIA CARDIA -SURGICAL CORRECTION 27000
CM0902-I : ACHALASIA CARDIA - LAP SURGICAL CORRECTION ( INCLUDING HELLERS MYOTOMY) 27000
CM0902-II : ACHALASIA CARDIA - LAP SURGICAL CORRECTION ( INCLUDING HELLERS MYOTOMY) 27000
CM0903 : ACHALASIA CARDIA -PNEUMATIC DILATATION 9405
CM0904 : LAP FUNDOPLICATIONS 40500
CM0905-I : CYST EXCISION WITH OR WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 40500
CM0905-II : CYST EXCISION WITH OR WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 40500
CM0907 : ENUCLEATION OF CYST 36000
CM0908A-I : OTHER BYPASS PANCREAS 36000
CM0908A-II : OTHER BYPASS PANCREAS 36000
CM0908B-I : TRIPLE BYPASS 36000
CM0908B-II : TRIPLE BYPASS 36000
CM0910 : PANCREATIC NECROSECTOMY OPEN 37800
CM0911 : PANCREATIC NECROSECTOMY LAP 37800
CM0916 : AV FISTULA ( INCLUDING PRE TRANSPLANTATION ) 8550
CM0917 : COMPLEX AV ACCESS WITH GRAFT FOR HEMODIALYSIS 25650
CM0918 A : URETEROSCOPY AND DJ STENTING U/L 5400
CM0918 B : URETEROSCOPY AND DJ STENTING B/L 8100
CM0919 : URETEROSCOPY AND DJ STENT REMOVAL 2700
CM0920 : TRANSURETHRAL RESECTION OF BLADDER TUMOR /RE-TURBT 27000
CM0921A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - OPEN 13500
CM0921B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - OPEN 31500
CM0921C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - OPEN 14400
CM0921D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - OPEN 18000
CM0921E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - OPEN 36000
CM0921F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - OPEN 18000
CM0922A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - LAP 13500
CM0922B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - LAP 31500
CM0922C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - LAP 14400
CM0922D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - LAP 18000
CM0922E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - LAP 36000
CM0922F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - LAP 18000
CM0924 : APPENDICULAR PERFORATION 13500
CM0925A : VAGOTOMY ANY TYPE WITHOUT DRAINAGE PROCEDURES 22500
CM0925B : VAGOTOMY ANY TYPE WITH DRAINAGE PROCEDURES 36000
CM0926 : OPERATION FOR BLEEDING PEPTIC ULCER 36000
CM0927 : PYLOROMYOTOMY 19800
CM0928 : OPERATIONS FOR RECURRENT INTESTINAL OBSTRUCTION (NOBLE PLICATION /OTHER) 31500
CM0929 : OPERATION FOR ACUTE INTESTINAL PERFORATION / PERFORATION PERITONITIS (INTESTINAL/GASTRIC/BILIARY)/ DUODENAL PERFORATION 27000
CM0930 : OPERATION FOR ACUTE INTESTINAL OBSTRUCTION (INCLUDING VOLVULUS / MALROTATION/INTUSUSCEPTION) 36000
CM0931-I : INVESTIGATION AND MANAGEMENT CHRONIC HEPATITIS B / C 158697
CM0932-I : CIRRHOSIS OF LIVER WITH COMPLICATIONS 27072
CM0935 : STAY IN GENERAL WARD - OBSERVATION FOR TRAUMA - PER DAY 630
CM0936 B : STAY IN ICU - MILD WITHOUT VENTILATION (FOR TRAUMA) 900
CM0936 C : STAY IN ICU - MODERATE WITHOUT VENTILATION (FOR TRAUMA) 13500
CM0936 D : STAY IN ICU - MODERATE WITH VENTILATION (FOR TRAUMA) 22500
CM0936 E : STAY IN ICU - SEVERE WITHOUT VENTILATION (FOR TRAUMA / POST OP COMPLICATIONS - Sepsis / coma) 22500
CM0936 F : STAY IN ICU - SEVERE WITH VENTILATION (FOR TRAUMA / POST OP COMPLICATIONS - Sepsis / Coma) 45000
CM0937 A : PYELOLITHOTOMY - OPEN 22500
CM0937 B : PYELOLITHOTOMY - LAP 22500
CM0938 A : NEPHROLITHOTOMY - OPEN 22500
CM0938 B : NEPHROLITHOTOMY - LAP 22500
CM0939 : OPEN CYSTOLITHOTOMY 12600
CM0940 A : URETEROLITHOTOMY - OPEN 18000
CM0940 B : URETEROLITHOTOMY - LAP 18000
CM0941 A : VESICOLITHOTOMY - OPEN 12600
CM0941 B : VESICOLITHOTOMY - LAP 12600
CM0951 A : TRANSVERSE MYELITIS WITH CENTRAL DEMYELINATION 90000
CM0951 B : TRANSVERSE MYELITIS WITHOUT CENTRAL DEMYELINATION 18000
CM0952A-I-i-a : Imatinib 1525
CM0952A-I-i-b : Nilotinib 17800
CM0952A-I-ii-a : Induction 12840
CM0952A-I-ii-b : Imatinib 1525
CM0952A-I-ii-c : Nilotinib 17800
CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine 12320
CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine 10365
CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose) 16725
CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine 12320
CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose) 29600
CM0952A-I-iii-f : Idarubicin + Cytarabine 23240
CM0952A-I-iii-g : mitoxantrone + Cytarabine 10820
CM0952A-I-iii-h : Imatinib 1525
CM0952A-I-iii-i : Nilotinib 17800
CM0952A-I-iii-ii : Other Regimen 10000
CM0952A-I-iii-iii : Other Regimen 10000
CM0952A-II-a : Daunorubicin + Cytarabine 1 12320
CM0952A-II-b : Idarubicin + Cytarabine 23240
CM0952A-II-c : Daunorubicin + Cytarabine 2 10365
CM0952A-II-d : Daunorubicin + Cytarabine (High Dose) 16725
CM0952A-II-e : Idarubicin + Cytarabine (High Dose) 29600
CM0952A-II-f : Daunorubicin (90mg) + Cytarabine 12320
CM0952A-II-g : idarubicin + Cytarabine 23240
CM0952A-II-h : mitoxantrone + Cytarabine 10280
CM0952A-II-i : Cytarabine 6800
CM0952A-II-j : Decitabine 25000
CM0952A-II-k : azacytidine 77500
CM0952A-II-l : Hydroxyurea 1600
CM0952A-II-m : Cytarabine - High Dose 9720
CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf 85150
CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf 40690
CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf 66710
CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone 13260
CM0952A-II-r : Cytarabine SC 2800
CM0952A-II-s : azacytidine 77500
CM0952A-II-t : Decitabine 25500
CM0952A-II-u : Other Regimen 10000
CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1 1084
CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3 25584
CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8 32984
CM0952A-III-a-iv : Maintanance - Rituximab 25500
CM0952A-III-b : Rituximab Day 1, 8, 15, and 22: 100500
CM0952A-III-c : Chlorambucil 2344
CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1) 36500
CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6) 37900
CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1) 12500
CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6) 6500
CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR) 31898
CM0952A-III-f : Fludarabine + rituximab (FR) 67930
CM0952A-III-g : Alemtuzumab + rituximab 108950
CM0952A-III-h : Alemtuzumab without rituximab 11450
CM0952A-III-i : High-dose methylprednisolone + rituximab 103955
CM0952A-III-j : High-dose methylprednisolone 6455
CM0952A-III-k : Other Regimen 10000
CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE 13340
CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 17095
CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 19175
CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION 25291
CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION 41425
CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks) 35621
CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks) 12836
CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 62380
CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 11469
CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 13420
CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II 15133
CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III 5535
CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance 9923
CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE 15133
CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I 8460
CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II 3700
CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE 3410
CM0952A-IV-i-c-5 : Imatinib 1525
CM0952A-IV-i-c-6 : Nilotinib 17800
CM0952A-IV-i-d : Other Regimen 10000
CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 62380
CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 11469
CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 13420
CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II 15133
CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III 5535
CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance 9923
CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE 15573
CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I 12110
CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II 3200
CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE 6410
CM0952A-IV-ii-b-5 : Imatinib 1525
CM0952A-IV-ii-b-6 : Nilotinib 17800
CM0952A-IV-ii-c : Corticosteroids + TKIs 9035
CM0952A-IV-ii-d : Other Regimen 10000
CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION 15678
CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE 28760
CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION 30779
CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course) 15495
CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course) 27210
CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance 56898
CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement: 21155
CM0952A-IV-iii-v : CCG-1961 18310
CM0952A-IV-iii-vi : Other Regimen 10000
CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION 18038
CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION 16685
CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7 60970
CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8 56820
CM0952A-IV-iii-c : Other Regimen 10000
CM0952-ii : Surgery for All Leukemias - Utilise Surgical Oncology Package if unavailable maximum payable 45000
CM0953A-I-a : ABVD 4480
CM0953A-I-b : Escalated BEACOPP 7119
CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks) 28480
CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD 102480
CM0953A-I-d-ii : ABVD 4480
CM0953A-I-e-i : CHOP + Rituximab 26818
CM0953A-I-e-ii : CHOP 2818
CM0953A-I-f-i : CVP +/- Rituximab 25768
CM0953A-I-f-ii : CVP 1768
CM0953A-I-g : Rituximab 25500
CM0953A-I-h : Other Regimen 10000
CM0953A-II-a : Bortezomib + dexamethasone 68038
CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab 26818
CM0953A-II-c : Rituximab 25500
CM0953A-II-d : Rituximab + cyclophosphamide + prednisone 25738
CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone 25520
CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2) 2540
CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50) 6000
CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52) 6000
CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16 24000
CM0953A-II-g-i : Bendamustine with or without rituximab 36500
CM0953A-II-g-ii : Bendamustine - rituximab 12500
CM0953A-II-h-i : Cladribine with or without rituximab 32250
CM0953A-II-h-ii : Cladribine - rituximab 8250
CM0953A-II-i : Bendamustine 12500
CM0953A-II-j : Chlorambucil 1126
CM0953A-II-k : Fludarabine 12030
CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR) 32398
CM0953A-II-m : Alemtuzumab 2650
CM0953A-II-n : Other Regimen 10000
CM0953A-III-i-a -1 : CALGB 10002 Cycle 1: 8967
CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6: 66113
CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7: 33108
CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6: 36413
CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab 46780
CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2) 32972
CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab 46780
CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab 42847
CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide) 32994
CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide) 43894
CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin) 32255
CM0953A-III-i-i : HDAC + Rituximab 27800
CM0953A-III-i-ii : Other Regimen 10000
CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction) 4580
CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy) 2100
CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-ii-c : CHOEP 8640
CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) 6892
CM0953A-III-ii-e : Other Regimen 10000
CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab 2500
CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 46780
CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 42847
CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) 32972
CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab 26818
CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-iii-f : Other Regimen 10000
CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab 2500
CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 46780
CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 42847
CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) 32972
CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-iv-f : Other Regimen 10000
CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-v-b : Rituximab 25500
CM0953A-III-v-c : Other Regimen 10000
CM0953A-III-vi-a-1 : Bendamustine with or without rituximab 36500
CM0953A-III-vi-a-2 : Bendamustine (-) rituximab 12500
CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP) 25768
CM0953A-III-vi-d : Rituximab 25500
CM0953A-III-vi-e : Lenalidomide + Rituximab 4940
CM0953A-III-vi-f : Other Regimen 10000
CM0953A-III-vii-a : SMILE 27483
CM0953A-III-vii-b : DeVIC +RT 9163
CM0953A-III-vii-c : VIPID 6619
CM0953A-III-vii-d : Other Regimen 10000
CM0953-ii : Surgery for All Lymphomas - Utilise Surgical Oncology Package if unavailable maximum payable 45000
CM0954-i-a : Lenalidomide 2575
CM0954-ii-a-1 : rHu-Epo with or without G-CSF 26080
CM0954-ii-a-2 : rHu-Epo (-) G-CSF 25750
CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF 9330
CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF 9000
CM0954-iii-a-1 : Decitabine (15mg/m2) 15500
CM0954-iii-a-2 : Decitabine (20mg/m2) 16500
CM0954-iii-b : Lenalidomide 2575
CM0955-a : Lenalidomide (28 days) + Dexamethasone 6817
CM0955-b : Lenalidomide (21 days) + Dexamethasone 5004
CM0955-c : Lenalidomide 2575
CM0955-d : Bendamustine + Lenalidomide + Dexamethasone 13639
CM0955-e : Bendamustine 22000
CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone 5136
CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP) 5764
CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE) 7724
CM0955-i : High-dose Cyclophosphamide 5140
CM0955-j : VAD / VAMP 6104
CM0955-k : Melphalan 3900
CM0955-l : Melphalan + Prednisolone 1137
CM0955-m : Thalidomide + Dexamethasone 2376
CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT) 2257
CM0959 : CYSTIC FIBROSIS 32940
CM0960 : SEPTIC SHOCK (ICU MANAGEMENT) 38745
CM0962-I : NEPHROTIC SYNDROME 14486
CM0962-II : NEPHROTIC SYNDROME 14486
CM0963-I : NEPHROTIC SYNDROME WITH COMPLICATIONS 23396
CM0963-II : NEPHROTIC SYNDROME WITH COMPLICATIONS 23396
CM0964-I : ACUTE DISSEMINATED ENCEPHALOMYELITIS 45000
CM0967-I : TOXIC/DRUG INDUCED LIVER INJURY 24120
CM0968 : MALIGNANT ASCITES 5085
CM0970 : SLEEVE RESECTION CA EAR 17550
CM0971 : SLEEVE RESECTION CA LUNG 21780
CM0973 : ENDOSCOPIC PARATHYROIDECTOMY 27000
CM0974-II : IVC FILTER REMOVAL 27315
CM0975A : IJV CATHETER INSERTION WITHOUT DIALYSIS 9000
CM0975B : IJV CATHETER INSERTION - INCLUDING DIALYSIS 11700
CM0978 : C-ARM GUIDED INTRA ARTICULAR INJECTIONS (SHOULDER / ELBOW / WRIST / HIP / KNEE / ANKLE / JOINTS OF FOOT AND HAND 14175
CM0982 : OP /ANY POISIONING - CONSERVATIVE MANAGEMENT OR WITHOUT VENTILATORY SUPPORT (ONLY WITH FIR ) 16200
CM0983 : MAXILLECTOMY WITH ORBITAL EXENTERATION 30915
CM0984 : MAXILLECTOMY WITH SKULL BASE RESECTION 33975
CM0987 : ACUTE SEVERE ASTHMA WITH VENTILATION 46080
CM0988 : CRITICAL CARE ICU MANAGEMENT ( RESPIRATORY DISTRESS/ METABOLIC COMA/MULTIORGAN DYSFUNCTION/SEPTIC SHOCK/OTHERS WITH VENTILATION 28350
CM0989A : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (heparinisation) 18000
CM0989B : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (SK) 22500
CM0989C : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (rTPA) 67500
FUP0046A : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY / THREE FIELD LYMPADENECTOMY - First Qtr 400
FUP0046B : OESOPHAGECTOMY WITH TWO FIELD LYMPADENECTOMY / THREE FIELD LYMPADENECTOMY - Next 3 Qtrs 400
FUP0047A : ALL - First Qtr 1000
FUP0047B : ALL - Next 3 Qtrs 750
FUP0048A : CML - First Qtr 1000
FUP0048B : CML - Next 3 Qtrs 750
FUP0049A : CLL - First Qtr 1000
FUP0049B : CLL - Next 3 Qtrs 750
FUP0050A : MYELODYSPLASTIC SYNDROME - First Qtr 1000
FUP0050B : MYELODYSPLASTIC SYNDROME - Next 3 Qtrs 750
FUP0051A : LYMPHOMA HODGKIN DISEASE - First Qtr 1000
FUP0051B : LYMPHOMA HODGKIN DISEASE - Next 3 Qtrs 750
FUP0052A : LYMPHOMA NON HODGKINS DISEASES - First Qtr 1000
FUP0052B : LYMPHOMA NON HODGKINS DISEASES - Next 3 Qtrs 750
FUP0076A : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - First Qtr 1800
FUP0076B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs 1000
FUP0077A : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - First Qtr 1800
FUP0077B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs 1000
FUP0092A : D V T - IVC FILTER - First Qtr 3500
FUP0092B : D V T - IVC FILTER - Next 3 Qtrs 1500
FUP0093A : AORTO-BIILIAC-BIFEOMRAL BYPASS WITH VEIN / SYNTHETIC GRAFT - First Qtr 3500
FUP0093B : AORTO-BIILIAC-BIFEOMRAL BYPASS WITH VEIN / SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0094A : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT - First Qtr 3500
FUP0094B : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0095A : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT - First Qtr 3500
FUP0095B : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0096A : NECK VASCULAR INJURY - CAROTID VESSELS - First Qtr 3500
FUP0096B : NECK VASCULAR INJURY - CAROTID VESSELS - Next 3 Qtrs 1500
FUP0097A : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - First Qtr 3500
FUP0097B : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Next 3 Qtrs 1500
FUP0098A : THORACIC VASCULAR INJURIES - First Qtr 3500
FUP0098B : THORACIC VASCULAR INJURIES - Next 3 Qtrs 1500
FUP0101A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr 1000
FUP0101B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs 500
FUP0102A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr 2500
FUP0102B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs 1000
FUP0103A : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - First Qtr 2500
FUP0103B : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - Next 3 Qtrs 2500
FUP0111A : RT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - First Qtr 2200
FUP0111B : RT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - Next 3 Qtrs 1200
FUP0112A : LT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - First Qtr 2200
FUP0112B : LT. HEPATECTOMY/NON ANATOMICAL RESECTION OF LIVER - Next 3 Qtrs 1200
FUP0113A : PORTOCAVAL ANASTOMOSIS - First Qtr 4000
FUP0113B : PORTOCAVAL ANASTOMOSIS - Next 3 Qtrs 2000
FUP0116A : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION - First Qtr 5000
FUP0116B : DEVASCULARISATION WITH OESOPHAGEAL TRANSECTION - Next 3 Qtrs 1500
FUP0118A : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION - First Qtr 2200
FUP0118B : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION - Next 3 Qtrs 1000
FUP0129A : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES - First Qtr 2000
FUP0148A : HEPATIC VEIN ANGIOPLASTY AND STENTING - First Qtr 3000
FUP0148B : HEPATIC VEIN ANGIOPLASTY AND STENTING - Next 3 Qtrs 1500
FUP0151A : MULTI ORGAN RESECTION FOR ANY GI CANCERS - First Qtr 1500
FUP0151B : MULTI ORGAN RESECTION FOR ANY GI CANCERS - Next 3 Qtrs 1000
FUP0152A : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR - First Qtr 2500
FUP0152B : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR - Next 3 Qtrs 1500
FUP0153A : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL - First Qtr 2500
FUP0153B : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL - Next 3 Qtrs 1200
FUP0154A : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL - First Qtr 2000
FUP0154B : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL - Next 3 Qtrs 2000
CM0100-N : BREAST CANCER - TAMOXIFEN 100
CM0100-O : BREAST CANCER - AROMATASE INHIBITORS 1000
CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis 2700
CM0124-c : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis 2700
CM0955-O : Multiple Myeloma - Zoledronic Acid 2700
CM0100-a-III : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 21 days for 4 cycles 7000
CM0100-a-IV : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 80mg/m2) Repeat cycle - weekly for 12 cycles 3500
CM0101-a-IV : BLADDER CANCER - Radiosensitizing - Cisplatinc + 5-FU ; Days 1, 2, 3, 15, 16, and 17: IV hydration at a rate of 500mL/hour; followed by 5-FU 400mg/m2 IV push; followed by cisplatin 15mg/m2 IV over 1 hour as induction and consolidation therapy 9800
CM0101-a-V : BLADDER CANCER -Radiosensitizing - Cisplatin + paclitaxel ; Days 1, 8, and 15: Paclitaxel 50mg/m2 ; Day 1-3, 8-10, 15-17: Cisplatin 15mg/m2; followed by twice-daily radiotherapy for 8 days 18400
CM0101-a-VI : BLADDER CANCER -Radiosensitizing - 5-FU + mitomycin32 ; Day 1 of radiotherapy: Mitomycin 12mg/m2 IV bolus, plus ; Week 1 (fractions 1-5) and Week 4 (fractions 16-20) of radiotherapy: 5-FU 500mg/m2 continuous IV infusion (10 days total) 15100
CM0101-c : BLADDER CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles 1800
CM0103-v: ESOPHAGEAL CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles 1800
CM0106-vi : Other bone tumors - Mesenchymal Chordosarcoma VIDE (vincristine + ifosfamide + doxorubicin + etoposide) ; Day 1: Vincristine 1.4mg/m2 (max 2mg), ; Days 1-3: Doxorubicin 20mg/m2 IV + ifosfamide 3mg/m2 IV + mesna 3g/m2 + etoposide 150mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. 9200
CM0114-i-b-1 : EWINGS SARCOMA - Induction Treatment - VAC/IE - VAC ; Day 1: Vincristine 2mg/m2 (max 2mg) IV, doxorubicin 75mg/m2 IV bolus, cyclophosphamide 1,200mg/m2 IV, mesna. ; Dactinomycin 1.25mg/m2 IV can be substituted for doxorubicin when a total doxorubicin dose of 375mg/m2 is reached. 4600
CM0114-i-b-2 : EWINGS SARCOMA - Induction Treatment - VAC/IE - IE ; IE cycles ; Days 1-5: Ifosfamide 1,800mg/m2 IV + mesna + etoposide 100mg/m2 IV. ; Repeat each cycle every 3 weeks for 17 cycles. 6000
CM0114-i-e : EWINGS SARCOMA - Induction Treatment - VACA ; Day 1: Vincristine 1.5mg/m2 IV + cyclophosphamide 1,200mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 10 cycles. 4600
CM0117-e : VULVAL CANCER - Cisplatin + 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV 11100
CM0128-ii-c-1 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) 7200
CM0128-ii-c-2 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - adjuvant temozolomide - preceeded by Concurrent Temozolomide (with RT) ; Temozolomide 150-200mg/m2/day for 5 days. ; Repeat cycle every 28 days for 6 cycles 2100
CM0130 I a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 I b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 I c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Bevacizumab + IFN-alpha ; Bevacizumab 10mg/kg IV every 2 weeks + IFN-alpha. 66750
CM0130 I d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 II a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Everolimus ; Everolimus 10mg orally once daily 37250
CM0130 II b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 II c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 II d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 II e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. 66250
CM0130 III a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 III b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. 66250
CM0130 III c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Everolimus ; Everolimus 10mg orally once daily 37250
CM0130 III d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Erlotinib ; Erlotinib 150mg orally once daily 3400
CM0130 III e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 III f : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 IV: RENAL CELL CARCINOMARENAL CELL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0131-i-g : UNKNOWN PRIMARY - Adenocarcinoma - mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles 8000
CM0131-i-h : UNKNOWN PRIMARY - Adenocarcinoma - CapeOX ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Day 1-14: Capecitabine 850-1000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 16 cycles. 6500
CM0131-i-i : UNKNOWN PRIMARY - Adenocarcinoma - Irinotecan + carboplatin ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for up to 6 cycles 7700
CM0131-ii-c : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + carboplatin ; Day 1: Carboplatin AUC 6mg per min/mL IV over 30 minutes + paclitaxel 200mg/m2 IV over 3 hours. ; Repeat cycle every 3 weeks for 8 cycles in responding patients and for 6 cycles maximum in patients with stable disease 7200
CM0131-ii-d : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + gemcitabine ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. 5250
CM0131-ii-e : UNKNOWN PRIMARY - Squamous cell carcinoma -mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles. 8000
CM0131-ii-f : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + cisplatin ; Day 1: Paclitaxel 175mg/m2 IV + cisplatin 60mg/m2 IV. ; Repeat cycle every 3 weeks. 6450
CM0131-ii-g : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + carboplatin ; Day 1: Docetaxel 75mg/m2 IV over 30 minutes + carboplatin AUC 5mg per min/mL IV over 30 minutes. ; Repeat cycle every 3 weeks for 8 cycles 8700
CM0131-ii-h : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 60mg/m2 IV + cisplatin 80mg/m2 IV. ; Repeat cycle every 3 weeks for 2 cycles and an additional 4 cycles until disease progression is demonstrated 5040
CM0131-ii-i : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. 3820
CM0131-ii-j : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + fluorouracil ; Days 1-5: Cisplatin 20mg/m2 IV ; Days 1-5: Fluorouracil 700mg/m2/day IV via continuous infusion over 24 hours. ; Repeat cycle every 4 weeks for 3 cycles. 7050
CM0630 B -II-c : MIXED CONNECTIVE TISSUE DISEASE - WITH GANGRENE ON IV PROSTACYCLIN 6300
CM0630 B -II-d : MIXED CONNECTIVE TISSUE DISEASE - PNEUMOCOCCAL VACCINATION 4500
CM0631A-II -a : VASCULITIS - PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE 2700
CM0631A-II -b : VASCULITIS - PULSE CYCLOPHOSPHAMIDE THERAPY 2700
CM0630 A-I-a-ii : MIXED CONNECTIVE TISSUE DISEASE- PULSE CYCLOPHOSPHAMIDE THERAPY 2700
CM0630 A-I-b-ii :MIXED CONNECTIVE TISSUE DISEASE-METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE 2700
CM0630 B -II-a : MYCOPHENOLATE MOFETIL INDUCTION 5400
CM0630 B -II-b : MYCOPHENOLATE MOFETIL MAINTENANCE 2700
CM0630 B -II-e : MIXED CONNECTIVE TISSUE DISEASE-(METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE/ PULSE CYCLOPHOSPHAMIDE THERAPY/ MYCOPHENOLATE MOFETIL INDUCTION/MYCOPHENOLATE MOFETIL MAINTENANCE/ WITH GANGRENE ON IV PROSTACYCLIN/ PNEUMOCOCCAL VACCIN 27000
CM0631A-II-c : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY )(including Diagnostic evaluation - 1st time) 10800
CM0707-II-A : ACUTE MILD PANCREATITIS - CONSERVATIVE MANAGEMENT 27000
CM0707-II-B : ACUTE MODERATE PANCREATITIS - CONSERVATIVE MANAGEMENT 36000
CM0707-II-C : ACUTE SEVERE PANCREATITIS - CONSERVATIVE MANAGEMENT 50355
CM0881 A-I-a : THALASSEMIA MAJOR (upto) 6300
CM0931-I-B : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 1 MG 30 TABS 1800
CM0931-I-C : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 0.5MG 30 TABS 3500
CM0931-I-F : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS 2000
CM0931-I-H : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS + VELPATASVIR 100 28 TABS 6000
CM0931-II-B : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 1 MG 30 TABS 4500
CM0931-II-D : MANAGEMENT CHRONIC HEPATITIS B / C - TELBUVUDINE 600MG 30 TABS 16000
CM0931-II-F : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS 11000
CM0931-I-ii : INVESTIGATION OF CHRONIC HEPATITIS B / C (VIRAL LOAD) 10000
CM0931-II-I : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS + LEDIPASVIR 90 28 TABS 15000
CM0931-II-i i: INVESTIGATION OF CHRONIC HEPATITIS B / C (VIRAL LOAD) 10000
CM0931-I-J : MANAGEMENT CHRONIC HEPATITIS B / C INTERFERON WILL BE APPROVED BASED ON DOSAGE) 1000
CM0879-I-a :LAPAROSCOPIC - ECTOPIC RESECTION 19215
CM0629-II-a : OBSCURE BLEED - Conservative management including Capsule endoscopy 27000
CM0629-II-b : OBSCURE BLEED - Conservative 9000
CM0629-II-c : NON VARICEAL BLEED - CLIPPING 27000
CM0629-II-d : NON VARICEAL BLEED - ARGON PLASMA COAGULATION 41535
CM0629-II-e : NON VARICEAL BLEED - CONSERVATIVE 9000
CM0774 A : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 18045
CM0820-I-A : Amputation of AK / BK 27000
CM0820-I-B : Amputation of AE / BE 22500
CM0820-I-C : Amputation of Fore-Foot 13500
CM0820-I-E : Amputation of Toes 6300
CM0820-I-F : Amputation of Fingers 9000
CM0820-I-G : Trans Meta-Tarsal Amputation 13500
CM0879-I-b :LAPROTOMY - ECTOPIC RESECTION 10800
CM0898 A : COLONIC PULL THROW 45000
CM0898 B : COLOPLASTY 27000
CM0898 C : ABDOMINAL RESECTION 36000
CM0905-IA : CYST EXCISION WITH HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 40500
CM0905-IB : CYST EXCISION WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 31500
CM0774 B : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 18045
CM0952A-I-iii-j : Chronic Myeloid Leukemia (CML) - Other Regimen 10000
CM0952A-II-z : Acute Myeloid Leukemia (AML) - Other Regimen 10000
CM0183a : Neck/ Shaft Of Femur ORIF 20025
CM0183b : IM Nailing 13500
CM0183c : Shaft of Other Long Bones (Humerus) 15300
CM0183d : Tibia 13500
CM0183e : Radius, Fibula, Ulna (ORIF) 13500
CM0183f : Clavicle ( CRIF) (Displaced) 7200
CM0183g : Clavicel (ORIF) (Displaced) 10800
CM0183h : Both Bones of Forearm, Both Bones of Leg (Fixation of both bones) 20025
CM0183i : Bimalleolar Fracture 13500
CM0183j : Closed Reduction and Proximal Femoral nailing / Screw Fixation 13500
CM0183k : Closed Reduction and Pinning / Tens Nail 10800
CM0183l : Closed Reduction and Internal Fixation with K wire 5400
CM0183m : Tension Band wiring 10800
CM0184a : Neck/ Shaft Of Femur ORIF 20025
CM0184b : IM Nailing 13500
CM0184c : Shaft of Other Long Bones (Humerus) 15300
CM0184d : Tibia 13500
CM0184e : Radius, Fibula, Ulna (ORIF) 13500
CM0184f : Clavicle ( CRIF) (Displaced) 7200
CM0184g : Clavicel (ORIF) (Displaced) 10800
CM0184h : Both Bones of Forearm, Both Bones of Leg (Fixation of both bones) 20025
CM0184i : Bimalleolar Fracture 13500
CM0184j : Closed Reduction and Proximal Femoral nailing / Screw Fixation 13500
CM0184k : Closed Reduction and Pinning / Tens Nail 10800
CM0184l : Closed Reduction and Internal Fixation with K wire 5400
CM0184m : Tension Band wiring 10800
CM0186A-i : IMPLANT EXIT- K-WIRES - Single 1350
CM0186A-ii : IMPLANT EXIT- K-WIRES - Multiple 2250
CM0186A-iii : IMPLANT EXIT- SCREWS - single (Open) 3600
CM0186A-iv : IMPLANT EXIT- SCREWS - Multiple (Open) 6750
CM0186A-v : IMPLANT EXIT- SCREWS - single (Closed) 1800
CM0186A-vi : IMPLANT EXIT- SCREWS - Multiple (Closed) 2700
CM0186A-vii : IMPLANT EXIT- OTHER MINOR IMPLANTS (TENS, TBW, etc) - Solitary 4500
CM0186A-viii : IMPLANT EXIT- OTHER MINOR IMPLANTS (Pins / TENS, TBW, etc) - Multiple 6975
CM0186B-i : IMPLANT EXIT- PLATES (Open) 11250
CM0186B-ii : IMPLANT EXIT- Femoral Screws / IM Nails / Rush Nail (Open) 9000
CM0186B-iii : IMPLANT EXIT- SPINE IMPLANTS - upto 2 levels(complete exit) (eg- L2-L3, L3-L4) 15750
CM0186B-iv : IMPLANT EXIT- SPINE IMPLANTS - upto 2 levels(partial exit) (eg- L2-L3, L3-L4) 13500
CM0186B-v : IMPLANT EXIT- SPINE IMPLANTS - > 2 levels(complete exit) (eg- L2-L3, L3-L4, L4-L5) 18450
CM0186B-vi : IMPLANT EXIT- SPINE IMPLANTS - > 2 levels(partial exit) (eg- L2-L3, L3-L4, L4-L5) 15750
CM0186B-vii : IMPLANT EXIT- Bipolar, etc 13500
CM0186B-viii : IMPLANT EXIT - Other Major implants 11250
CM0187a : ARTHRODESIS OF JOINTS - HIP 24300
CM0187b : ARTHRODESIS OF JOINTS - SHOULDER / KNEE 18000
CM0187c : ARTHRODESIS OF JOINTS - ELBOW/ ANKLE / WRIST 13500
CM0187d : ARTHRODESIS OF JOINTS - ANKLE - Triple Arthrodesis 14400
CM0187e : ARTHRODESIS OF JOINTS - HAND / FOOT 9000
CM0192-A : ILIZAROV RING FIXATOR APPLICATION-FEMUR - DEFORMITY CORRECTION / LIMB LENGTHENING 22500
CM0192-B : ILIZAROV RING FIXATOR APPLICATION- TIBIA - DEFORMITY CORRECTION / LIMB LENGTHENING 16200
CM0193-A : SURGERY FOR NEGLECTED CTEV/RECURRENT CTEV/RESISTANT CTEV BY JESS FIXATION 40275
CM0195-A : KNEE LIGAMENT RECONSTRUCTION-ACL RECONSTRUCTION/PCL RECONSTRUCTION 27000
CM0195-B : KNEE LIGAMENT RECONSTRUCTION-MPFL RECONSTRUCTION 22500
CM0204- b : ACETABULAR FRACTURES 26550
CM0204-a : CORRECTION SACRO ILLIAC JOINT 18000
CM0625-II A : AMPUTATIONS - FORE QUARTER 36000
CM0625-II B : AMPUTATIONS - HIND QUARTER / Internal Hemipelvectomy 36000
CM0625-II C : AMPUTATIONS - HIND QUARTER / External Hemipelvectomy 36000
CM0722-II-A : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MAXILLA 9023
CM0722-II-B : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE 9023
CM0722-II-C : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA- INTERDENTAL WIRING 4500
CM0807-a - I : Cementing (only as Addon) 4500
CM0807-a : BONE RESECTION 22500
CM0807-b - I : Cementing (only as Add on) 4500
CM0807-b : BONE Curettage 13500
CM0820-II-A : Amputation of AK / BK 27000
CM0820-II-B : Amputation of AE / BE 22500
CM0820-II-C : Amputation of Fore-Foot 13500
CM0820-II-E : Amputation of Toes 6300
CM0820-II-F : Amputation of Fingers 9000
CM0820-II-G : Trans Meta-Tarsal Amputation 13500
CM0820-III-a : Amputation of great toe 6300
CM0820-III-b : Amputation toe- single 4500
CM0820-III-c : Amputation toe- Multiple 6300
CM0820-III-d : Amputation of Finger - single 6300
CM0820-III-e : Amputation of Finger - Multiple 9000
CM0820-III-f : Transmetatarsal Amputation 9000
CM0861-II-A : POSTERIOR DISCECTOMY WITH SPACER/IMPLANT/VERTEBROPLASTY (open) 38700
CM0861-II-B : POSTERIOR DISCECTOMY WITH BONE GRAFT 29700
CM0861-II-C : POSTERIOR DISCECTOMY WITHOUT BONE GRAFT/SPACER/IMPLANT/VERTEBROPLASTY 22500
CM0629-I-a : OBSCURE BLEED - Conservative management including Capsule endoscopy 27000
CM0629-I-b : OBSCURE BLEED - Conservative 9000
CM0629-I-c : NON VARICEAL BLEED - CLIPPING 27000
CM0629-I-d : NON VARICEAL BLEED - ARGON PLASMA COAGULATION 41535
CM0629-I-e : NON VARICEAL BLEED - CONSERVATIVE 9000
CM0694-I-a : BILIARY DRAINAGE PROCEDURES - T- Tube 18000
CM0694-I-b : BILIARY DRAINAGE PROCEDURES - Choledocojejunostomy 31500
CM0694-I-c : BILIARY DRAINAGE PROCEDURES - Hepaticojejunostomy 40500
CM0694-I-d : ERCP and Stent (plastic) 22500
CM0694-I-e : ERCP and Stent (SEMS) 49500
CM0694-I-f : POST OP BILIARY STRICTURE 31500
CM0905-IBI : CYST EXCISION WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 31500
CM0905-IIA : CYST EXCISION WITH HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 40500
CM0775-I-a : SALPINGO OOPHORECTOMY B/L- FOR CA 22815
CM0775-I-b : SALPINGO OOPHORECTOMY U/L FOR CA 16200
CM0625-I A : AMPUTATIONS - FORE QUARTER 36000
CM0625-I B : AMPUTATIONS - HIND QUARTER / Internal Hemipelvectomy 36000
CM0625-I C : AMPUTATIONS - HIND QUARTER / External Hemipelvectomy 36000
CM0765A : GLOSSECTOMY (HEMI/PARTIAL) WITH RECONSTRUCTION- FOR CANCER 27000
CM0765B : GLOSSECTOMY (TOTAL) WITH RECONSTRUCTION- FOR CANCER 35865
CM0338-A : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Limbs) < 3 sq CM Surface Area 13500
CM0338-B : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Limbs) 3 to 6 CM 18000
CM0338-C : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Others) < 3 CM 22500
CM0338-D : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Others) 3 to 6 CM 27000
CM0338-E : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Brain) < 6 CM 35775
CM0339-A : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Brain) > 6 CM 66600
CM0339-B : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Limbs) > 6 CM 22500
CM0339-C : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Others) > 6 CM 36000
CM0343-A : MEDIUM SIZE ARTERIAL ANEURYSMS (eg. Radial, cephalic, brachial, etc) - Repair 31500
CM0343-B : MEDIUM SIZE ARTERIAL ANEURYSMS (eg. Carotid, Jugular, Femoral, etc) - Repair 41850
CM0344-A : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT (eg. Radial, cephalic, brachial, etc) 54000
CM0344-B : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT(eg. Carotid, Jugular, Femoral, etc) 66150
CM0347A-i : AORTO - ILLIAC BYPASS WITH VEIN 45000
CM0347A-ii : AORTO - FEMORAL BYPASS WITH VEIN 54000
CM0347B-i : AORTO - BILLIAC BYPASS WITH VEIN 63000
CM0347B-ii : AORTO - BIFEMORAL BYPASS WITH VEIN 71325
CM0347C-i : AORTO - ILLIAC BYPASS WITH SYNTHETIC GRAFT 63000
CM0347C-ii : AORTO - FEMORAL BYPASS WITH SYNTHETIC GRAFT 72000
CM0347D-i : AORTO - BILLIAC BYPASS WITH VEIN WITH SYNTHETIC GRAFT 73350
CM0347D-ii : AORTO - BIFEMORAL BYPASS WITH VEIN WITH SYNTHETIC GRAFT 83475
CM0367-A : VASCULAR INJURY IN UPPER LIMBS - AXILLARY REPAIR WITH VEIN GRAFT 30600
CM0367-B : VASCULAR INJURY IN UPPER LIMBS - BRACHIAL - REPAIR WITH VEIN GRAFT 22500
CM0367-C : VASCULAR INJURY IN UPPER LIMBS - RADIAL AND ULNAR - REPAIR WITH VEIN GRAFT 18000
CM0368A : MAJOR VASCULAR INJURY -REPAIR (Femoral) 37575
CM0368B : MAJOR VASCULAR INJURY -REPAIR (Tibial) 31500
CM0369A : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Fibular, Popliteal) 16425
CM0369B : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Foot) 10800
CM0369C : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Digits) 7200
CM0373A : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Vein Graft 63000
CM0373B : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Synthetic Graft 81675
CM0375A : VARICOSE VEINS RFA FOR U/L 15750
CM0377C : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (Systemic) - STK 9000
CM0377D : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (Systemic) - RTPA 27000
CM0384A : PSEUDOANEURYSM LIGATION - Small vessels (eg. Radial, cephalic, brachial, etc) 13500
CM0384B : PSEUDOANEURYSM LIGATION - Medium vessels (eg. Carotid, Jugular, Femoral, etc) 27000
CM0384C : PSEUDOANEURYSM LIGATION - Large vessels (eg. Aorta, Iliac, IVC, etc) 31275
CM0384D : PSEUDOANEURYSM LIGATION -Post AV Fistula 9000
CM0395A : GRAFT THROMBECTOMY BYPASS 19125
CM0395B : AV ACCESS SURGERY (not for Dialysis) 13500
CM0674-II-a : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Balloon plasty 52425
CM0674-II-b : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Stenting 83925
CM0692-II-A : ACUTE STROKE THROMBOLYSIS (R TPA ) (Cathter Directed) 67725
CM0814-I-a : VASCULAR MALFORMATIONS- Sclerotherapy 11700
CM0814-I-b : VASCULAR MALFORMATIONS- Sclerotherapy and Excision 23625
CM1038 : Drainage of Subdiaphramatic Abscess 9000
CM1046 : Excision Benign Tumor -Small intestine 13500
CM1067 : IlieoSigmoidostomy 15300
CM1076 : Repair of Common Bile Duct 13500
CM1083 : Pharyngectomy& Reconstruction - Total 18000
CM1084 : Tracheoplasty (Throat) 13500
CM1088 : Estlander Operation (lip) 6300
CM1093 : Operation for carcinoma lip- cheek advancement 10800
CM1096 : Resection Enucleation of Adenoma (lung) 9000
CM1099 : Thoracoplasty 18000
CM1100 : Thoracoscopic Segmental Resection 22500
CM1101 : Thoracoscopic Sympathectomy 13500
CM1191 : Abdominal Perineal neo construction Cx + Uteria + Vagina 18000
CM1198 : Brust abdomen repair 12600
CM1212 : Intrauterine transfusions 9000
CM1220 : Fixator with Joint Arthrolysis 18000
CM1223 : Pelvic Osteotomy with fixation with plaster 27000
CM1231 : Endopyelotomy (retrograde with laser/bugbee) 22500
CM1232 : Endopyelotomy (antegrade with laser/bugbee) 25200
CM1233 : Ureterocalycostomy Open 22500
CM1234 : Ureterocalycostomy Laparoscopic 27000
CM1235 : Uretero-ureterostomy Open 22500
CM1236 : Uretero-ureterostomy Laparoscopic 31500
CM1252 : Holmium Laser Prostatectomy 36000
CM1313 : Operations for Congenital Arteriovenous Fistula 15000
CM1323 : Microvascular reconstruction 40500
CM1325 : Axillary dissection 13500
CM1326 : Enucleation of pancreatic neoplasm 22500
CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 20000
CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage 30000
CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 15000
CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 25000
CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 50000
CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 20000
CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month 3000
CM0692-II-B-i : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 50 mg) 30300
CM0692-II-B-ii : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 70mg) 48300
CM0692-III : ACUTE STROKE THROMBOLYSIS (R TPA ) 67725
CM0692-III-B-i : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 50 mg) 30300
CM0692-III-B-ii : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 70mg) 48300

Say hello to us , Toll-Free

1800 425 3993

Write to us

[email protected]
[email protected]

Reach us At

The Project Director

Tamil Nadu Health Systems Project (TNHSP)
3rd Floor, DMS Annex New Building
259 Anna Salai, Teynampet
Chennai - 600 006, Tamil Nadu.

CMCHIS Project Office

Chief Minister's Comprehensive Health Insurance Scheme
No.226,Om Sakthi Towers,
Kilpauk Garden Road, Kilpauk,
Chennai-600010, Tamil Nadu

Scan QR Code or Click Here to Download the Mobile app for Beneficiary

Visitors Count : 2069 / 23251476